INDICATIONS AND USAGE

TIVICAY® (dolutegravir) tablets, for oral use

Full prescribing information: contents*

These highlights do not include all the information needed to use TIVICAY safely and effectively. See full prescribing information for TIVICAY.

TIVICAY® (dolutegravir) tablets, for oral use

Initial U.S. Approval: 2013

Recent major changes: dosage and administration, pediatric patients (2.2) 06/2016

Indications and usage

TIVICAY is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 30 kg. (1)

Limitations of use:

• Use of TIVICAY in integrase strand transfer inhibitor (INSTI) experienced patients should be guided by the number and type of baseline INSTI substitutions. The efficacy of TIVICAY 50 mg twice daily is reduced in patients with an INSTI-resistance Q148 substitution plus 2 or more additional INSTI-resistance substitutions including T66A, L74F/M, E138A/K/T, G140S/A/C, Y143R/C/H, E157Q, G163S/E/R/Q, or G193E/R. (12.4)

Dosage and administration

May be taken without regard to food. (2)

Adult Population

Recommended Dose

Treatment-naïve or treatment-experienced INSTI-naïve (2.1) 50 mg once daily

Treatment-naïve or treatment-experienced INSTI-naïve when coadministered with certain UGT1A or CYP3A inducers (2.1, 7.3) 50 mg twice daily

INSTI-experienced with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance (12.4) 50 mg twice daily

*Alternative combinations that do not include metabolic inducers should be considered where possible.

Pediatric Patients: (Treatment-naïve or treatment-experienced INSTI-naïve patients weighing at least 30 kg) (2.2)

• If at least 40 kg: The recommended dose is TIVICAY 50 mg once daily.

• Patients 30 kg to less than 40 kg: The recommended dose is TIVICAY 35 mg once daily.

• If certain UGT1A or CYP3A inducers are coadministered, then adjust the weight-based dose of TIVICAY to twice daily. (2.2, 7.3)

Dosage forms and strengths

Tablets: 10 mg, 25 mg, and 50 mg (3)

Full prescribing information: contents*

1 Indications and usage

2 Dosage and administration

2.1 Adults

2.2 Pediatric Patients

3 Dosage forms and strengths

4 Contraindications

5 Warnings and precautions

5.1 Hypersensitivity reactions

5.2 Effects on serum liver biochemistries in patients with hepatitis B or C co-infection

5.3 Fat redistribution

5.4 Immune reconstitution syndrome

6 Adverse reactions

6.1 Clinical Trials Experience

6.2 Postmarketing Experience

7 Drug interactions

7.1 Effect of Dolutegravir on the pharmacokinetics of other agents

7.2 Effect of Other Agents on the Pharmacokinetics of Dolutegravir

7.3 Established and other potentially significant drug interactions

8 Use in specific populations

8.1 Pregnancy

8.2 Lactation

8.4 Pediatric use

8.5 Geriatric use

8.6 Hepatic impairment

8.7 Renal Impairment

10 Overdosage

11 Description

12 Clinical pharmacology

12.1 Mechanism of action

12.2 Pharmacodynamics

12.3 Pharmacokinetics

12.4 Microbiology

13 Nonclinical Toxicology

13.1 Carcinogenesis, mutagenesis, Impairment of fertility

14 Clinical studies

14.1 Adult subjects

14.2 Pediatric Subjects

16 How supplied/storage and handling

17 Patient counseling information

*Sections or subsections omitted from the full prescribing information are not listed.

Revised: 03/2017

To report suspected adverse reactions, contact ViiV Healthcare at 1-877-844-8872 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Drug interactions

• Drugs that are metabolic inducers may decrease the plasma concentrations of dolutegravir. (7.2, 7.3)

• TIVICAY should be taken 2 hours before or 6 hours after taking cation-containing antacids or laxatives, sucralfate, oral supplements containing iron or calcium, or buffered medications. Alternatively, TIVICAY and supplements containing calcium or iron can be taken together with food. (7.3)

Use in specific populations

• Pregnancy: TIVICAY should be used during pregnancy only if the potential benefit justifies the potential risk. (8.1)

• Lactation: Breast feeding is not recommended. (8.2)

See 17 for patient counseling information and FDA-approved patient labeling.
FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

TIVICAY is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 30 kg.

Limitations of Use:

- Use of TIVICAY in integrase strand transfer inhibitor (INSTI)-experienced patients should be guided by the number and type of baseline INSTI substitutions. The efficacy of TIVICAY 50 mg twice daily is reduced in patients with an INSTI-resistance Q148 substitution plus 2 or more additional INSTI-resistance substitutions, including T66A, L74I/M, E138A/K/T, G140S/A/C, Y143R/C/H, E157Q, G163S/E/K/Q, or G193E/R [see Microbiology (12.4)].

2 DOSAGE AND ADMINISTRATION

2.1 Adults

TIVICAY tablets may be taken with or without food.

Table 1. Dosing Recommendations for TIVICAY in Adult Patients

<table>
<thead>
<tr>
<th>Population</th>
<th>Recommended Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment-naïve or treatment-experienced INSTI-naïve</td>
<td>50 mg once daily</td>
</tr>
<tr>
<td>Treatment-naïve or treatment-experienced INSTI-naïve when coadministered with certain UGT1A or CYP3A inducers [see Drug Interactions (7.3)]</td>
<td>50 mg twice daily</td>
</tr>
<tr>
<td>INSTI-experienced with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance[a] [see Microbiology (12.4)]</td>
<td>50 mg twice daily</td>
</tr>
</tbody>
</table>

[a] Alternative combinations that do not include metabolic inducers should be considered where possible [see Drug Interactions (7)].

2.2 Pediatric Patients

TIVICAY tablets may be taken with or without food.

Treatment-Naïve or Treatment-Experienced INSTI-Naïve

The recommended dose of TIVICAY in pediatric patients weighing at least 30 kg is provided in Table 2.
### Table 2. Dosing Recommendations for TIVICAY in Pediatric Patients Weighing at Least 30 kg

<table>
<thead>
<tr>
<th>Body Weight (kg)</th>
<th>Daily Dosea</th>
<th>(Number of Tablets per Dose when Different Strength(s) are Required)</th>
</tr>
</thead>
<tbody>
<tr>
<td>30 to less than 40</td>
<td>35 mg once daily</td>
<td>(One 25-mg tablet and one 10-mg tablet)</td>
</tr>
<tr>
<td>40 or greater</td>
<td>50 mg once daily</td>
<td></td>
</tr>
</tbody>
</table>

a If certain UGT1A or CYP3A inducers are coadministered, then increase the weight-based dose of TIVICAY to twice daily [see Drug Interactions (7.3) for relevant inducers].

Safety and efficacy of TIVICAY have not been established in pediatric patients who are INSTI-experienced with documented or clinically suspected resistance to other INSTIs (raltegravir, elvitegravir).

### 3 DOSAGE FORMS AND STRENGTHS

Tablets:

- **10 mg**: Each tablet contains 10 mg of dolutegravir (as dolutegravir sodium). Tablets are white, round, film-coated, biconvex tablets debossed with “SV 572” on one side and “10” on the other side.
- **25 mg**: Each tablet contains 25 mg of dolutegravir (as dolutegravir sodium). Tablets are pale yellow, round, film-coated, biconvex tablets debossed with “SV 572” on one side and “25” on the other side.
- **50 mg**: Each tablet contains 50 mg of dolutegravir (as dolutegravir sodium). Tablets are yellow, round, film-coated, biconvex tablets debossed with “SV 572” on one side and “50” on the other side.

### 4 CONTRAINDICATIONS

TIVICAY is contraindicated in patients:

- with previous hypersensitivity reaction to dolutegravir [see Warnings and Precautions (5.1)].
- receiving dofetilide due to the potential for increased dofetilide plasma concentrations and the risk for serious and/or life-threatening events [see Drug Interactions (7)].

### 5 WARNINGS AND PRECAUTIONS

#### 5.1 Hypersensitivity Reactions

Hypersensitivity reactions have been reported and were characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury. The events were reported in less than 1% of subjects receiving TIVICAY in Phase 3 clinical trials. Discontinue TIVICAY and other suspect agents immediately if signs or symptoms of hypersensitivity reactions develop.
(including, but not limited to, severe rash or rash accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters or peeling of the skin, oral blisters or lesions, conjunctivitis, facial edema, hepatitis, eosinophilia, angioedema, difficulty breathing). Clinical status, including liver aminotransferases, should be monitored and appropriate therapy initiated. Delay in stopping treatment with TIVICAY or other suspect agents after the onset of hypersensitivity may result in a life-threatening reaction. TIVICAY is contraindicated in patients who have experienced a previous hypersensitivity reaction to dolutegravir.

5.2 Effects on Serum Liver Biochemistries in Patients with Hepatitis B or C Co-infection

Patients with underlying hepatitis B or C may be at increased risk for worsening or development of transaminase elevations with use of TIVICAY [see Adverse Reactions (6.1)]. In some cases the elevations in transaminases were consistent with immune reconstitution syndrome or hepatitis B reactivation particularly in the setting where anti-hepatitis therapy was withdrawn. Appropriate laboratory testing prior to initiating therapy and monitoring for hepatotoxicity during therapy with TIVICAY are recommended in patients with underlying hepatic disease such as hepatitis B or C.

5.3 Fat Redistribution

Redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and “cushioningoid appearance” have been observed in patients receiving antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established.

5.4 Immune Reconstitution Syndrome

Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including TIVICAY. During the initial phase of combination antiretroviral treatment, patients whose immune systems respond may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium infection, cytomegalovirus, Pneumocystis jirovecii pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment.

Autoimmune disorders (such as Graves’ disease, polymyositis, and Guillain-Barré syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable and can occur many months after initiation of treatment.

6 ADVERSE REACTIONS

The following serious adverse drug reactions are discussed in other sections of the labeling:

- Hypersensitivity reactions [see Warnings and Precautions (5.1)].
- Effects on serum liver biochemistries in patients with hepatitis B or C co-infection [see
Warnings and Precautions (5.2)].

- Fat Redistribution [see Warnings and Precautions (5.3)].
- Immune Reconstitution Syndrome [see Warnings and Precautions (5.4)].

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Clinical Trials Experience in Adult Subjects

Treatment-Naïve Subjects: The safety assessment of TIVICAY in HIV-1-infected treatment-naïve subjects is based on the analyses of data from 2 international, multicenter, double-blind trials, SPRING-2 (ING113086) and SINGLE (ING114467) and data from the international, multicenter, open-label FLAMINGO (ING114915) trial.

In SPRING-2, 822 subjects were randomized and received at least 1 dose of either TIVICAY 50 mg once daily or raltegravir 400 mg twice daily, both in combination with fixed-dose dual nucleoside reverse transcriptase inhibitor (NRTI) treatment (either abacavir sulfate and lamivudine [EPZICOM®] or emtricitabine/tenofovir [TRUVADA®]). There were 808 subjects included in the efficacy and safety analyses. Through 96 weeks, the rate of adverse events leading to discontinuation was 2% in both treatment arms.

In SINGLE, 833 subjects were randomized and received at least 1 dose of either TIVICAY 50 mg with fixed-dose abacavir sulfate and lamivudine (EPZICOM) once daily or fixed-dose efavirenz/emtricitabine/tenofovir (ATRIPLA®) once daily (study treatment was blinded through Week 96 and open-label from Week 96 through Week 144). Through 144 weeks, the rates of adverse events leading to discontinuation were 4% in subjects receiving TIVICAY 50 mg once daily + EPZICOM and 14% in subjects receiving ATRIPLA once daily.

Treatment-emergent adverse drug reactions (ADRs) of moderate to severe intensity observed in at least 2% of subjects in either treatment arm in SPRING-2 and SINGLE trials are provided in Table 3. Side-by-side tabulation is to simplify presentation; direct comparisons across trials should not be made due to differing trial designs.
Table 3. Treatment-Emergent Adverse Drug Reactions of at Least Moderate Intensity (Grades 2 to 4) and at Least 2% Frequency in Treatment-Naïve Subjects in SPRING-2 (Week 96 Analysis) and SINGLE Trials (Week 144 Analysis)

<table>
<thead>
<tr>
<th>System Organ Class/Preferred Term</th>
<th>SPRING-2</th>
<th>SINGLE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Psychiatric</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insomnia</td>
<td>&lt;1%</td>
<td>&lt;1%</td>
</tr>
<tr>
<td>Depression</td>
<td>&lt;1%</td>
<td>&lt;1%</td>
</tr>
<tr>
<td>Abnormal dreams</td>
<td>&lt;1%</td>
<td>&lt;1%</td>
</tr>
<tr>
<td><strong>Nervous System</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dizziness</td>
<td>&lt;1%</td>
<td>&lt;1%</td>
</tr>
<tr>
<td>Headache</td>
<td>&lt;1%</td>
<td>&lt;1%</td>
</tr>
<tr>
<td><strong>Gastrointestinal</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>1%</td>
<td>1%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>&lt;1%</td>
<td>&lt;1%</td>
</tr>
<tr>
<td><strong>Skin and Subcutaneous Tissue</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rash(^a)</td>
<td>0</td>
<td>&lt;1%</td>
</tr>
<tr>
<td><strong>General Disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatigue</td>
<td>&lt;1%</td>
<td>&lt;1%</td>
</tr>
<tr>
<td><strong>Ear and Labyrinth</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vertigo</td>
<td>0</td>
<td>&lt;1%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TIVICAY 50 mg Once Daily + 2 NRTIs (n = 403)</th>
<th>Raltegravir 400 mg Twice Daily + 2 NRTIs (n = 405)</th>
<th>TIVICAY 50 mg + EPZICOM Once Daily (n = 414)</th>
<th>ATRIPLA Once Daily (n = 419)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SPRING-2</td>
<td>SINGLE</td>
<td>SPRING-2</td>
<td>SINGLE</td>
</tr>
<tr>
<td><strong>Psychiatric</strong></td>
<td></td>
<td><strong>Psychiatric</strong></td>
<td></td>
</tr>
<tr>
<td>Insomnia</td>
<td>&lt;1%</td>
<td>Depression</td>
<td>&lt;1%</td>
</tr>
<tr>
<td>Depression</td>
<td>&lt;1%</td>
<td>Insomnia</td>
<td>&lt;1%</td>
</tr>
<tr>
<td>Abnormal dreams</td>
<td>&lt;1%</td>
<td>Abnormal dreams</td>
<td>&lt;1%</td>
</tr>
<tr>
<td><strong>Nervous System</strong></td>
<td></td>
<td><strong>Nervous System</strong></td>
<td></td>
</tr>
<tr>
<td>Dizziness</td>
<td>&lt;1%</td>
<td>Dizziness</td>
<td>&lt;1%</td>
</tr>
<tr>
<td>Headache</td>
<td>&lt;1%</td>
<td>Headache</td>
<td>&lt;1%</td>
</tr>
<tr>
<td><strong>Gastrointestinal</strong></td>
<td></td>
<td><strong>Gastrointestinal</strong></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>1%</td>
<td>Nausea</td>
<td>1%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>&lt;1%</td>
<td>Diarrhea</td>
<td>&lt;1%</td>
</tr>
<tr>
<td><strong>Skin and Subcutaneous Tissue</strong></td>
<td></td>
<td><strong>Skin and Subcutaneous Tissue</strong></td>
<td></td>
</tr>
<tr>
<td>Rash(^a)</td>
<td>0</td>
<td>Rash(^a)</td>
<td>0</td>
</tr>
<tr>
<td><strong>General Disorders</strong></td>
<td></td>
<td><strong>General Disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Fatigue</td>
<td>&lt;1%</td>
<td>Fatigue</td>
<td>&lt;1%</td>
</tr>
<tr>
<td><strong>Ear and Labyrinth</strong></td>
<td></td>
<td><strong>Ear and Labyrinth</strong></td>
<td></td>
</tr>
<tr>
<td>Vertigo</td>
<td>0</td>
<td>Vertigo</td>
<td>0</td>
</tr>
</tbody>
</table>

\(^a\) Includes pooled terms: rash, rash generalized, rash macular, rash maculo-papular, rash pruritic, and drug eruption.

In addition, Grade 1 insomnia was reported by 1% and less than 1% of subjects receiving TIVICAY and raltegravir, respectively, in SPRING-2; whereas in SINGLE the rates were 7% and 4% for TIVICAY and ATRIPLA, respectively. These events were not treatment limiting.

In a multicenter, open-label trial (FLAMINGO), 243 subjects received TIVICAY 50 mg once daily versus 242 subjects who received darunavir 800 mg/ritonavir 100 mg once daily, both in combination with investigator-selected NRTI background regimen (either EPZICOM or TRUVADA). There were 484 subjects included in the efficacy and safety analyses. Through 96 weeks, the rates of adverse events leading to discontinuation were 3% in subjects receiving TIVICAY and 6% in subjects receiving darunavir/ritonavir. The ADRs observed in FLAMINGO were generally consistent with those seen in SPRING-2 and SINGLE.
Treatment-Experienced, Integrase Strand Transfer Inhibitor-Naïve Subjects: In an international, multicenter, double-blind trial (ING111762, SAILING), 719 HIV-1-infected, antiretroviral treatment-experienced adults were randomized and received either TIVICAY 50 mg once daily or raltegravir 400 mg twice daily with investigator-selected background regimen consisting of up to 2 agents, including at least one fully active agent. At 48 weeks, the rates of adverse events leading to discontinuation were 3% in subjects receiving TIVICAY 50 mg once daily + background regimen and 4% in subjects receiving raltegravir 400 mg twice daily + background regimen.

The only treatment-emergent ADR of moderate to severe intensity with at least 2% frequency in either treatment group was diarrhea, 2% (6 of 354) in subjects receiving TIVICAY 50 mg once daily + background regimen and 1% (5 of 361) in subjects receiving raltegravir 400 mg twice daily + background regimen.

Treatment-Experienced, Integrase Strand Transfer Inhibitor-Experienced Subjects: In a multicenter, open-label, single-arm trial (ING112574, VIKING-3), 183 HIV-1-infected, antiretroviral treatment-experienced adults with virological failure and current or historical evidence of raltegravir and/or elvitegravir resistance received TIVICAY 50 mg twice daily with the current failing background regimen for 7 days and with optimized background therapy from Day 8. The rate of adverse events leading to discontinuation was 4% of subjects at Week 48.

Treatment-emergent ADRs in VIKING-3 were generally similar compared with observations with the 50-mg once-daily dose in adult Phase 3 trials.

Less Common Adverse Reactions Observed in Treatment-Naïve and Treatment-Experienced Trials: The following ADRs occurred in less than 2% of treatment-naïve or treatment-experienced subjects receiving TIVICAY in a combination regimen in any one trial. These events have been included because of their seriousness and assessment of potential causal relationship.

Gastrointestinal Disorders: Abdominal pain, abdominal discomfort, flatulence, upper abdominal pain, vomiting.

Hepatobiliary Disorders: Hepatitis.

Musculoskeletal Disorders: Myositis.

Psychiatric Disorders: Suicidal ideation, attempt, behavior, or completion. These events were observed primarily in subjects with a pre-existing history of depression or other psychiatric illness.

Renal and Urinary Disorders: Renal impairment.

Skin and Subcutaneous Tissue Disorders: Pruritus.

Laboratory Abnormalities:
Treatment-Naïve Subjects: Selected laboratory abnormalities (Grades 2 to 4) with a worsening grade from baseline and representing the worst-grade toxicity in at least 2% of subjects are presented in Table 4. The mean change from baseline observed for selected lipid values is presented in Table 5. Side-by-side tabulation is to simplify presentation; direct comparisons across trials should not be made due to differing trial designs.

Table 4. Selected Laboratory Abnormalities (Grades 2 to 4) in Treatment-Naïve Subjects in SPRING-2 (Week 96 Analysis) and SINGLE Trials (Week 144 Analysis)

<table>
<thead>
<tr>
<th>Laboratory Parameter</th>
<th>SPRING-2</th>
<th>SINGLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preferred Term</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TIVICAY 50 mg Once Daily + 2 NRTIs (n = 403)</td>
<td>Raltegravir 400 mg Twice Daily + 2 NRTIs (n = 405)</td>
<td>TIVICAY 50 mg + EPZICOM Once Daily (n = 414)</td>
</tr>
<tr>
<td>ALT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade 2 (&gt;2.5-5.0 x ULN)</td>
<td>4%</td>
<td>4%</td>
</tr>
<tr>
<td>Grade 3 to 4 (&gt;5.0 x ULN)</td>
<td>2%</td>
<td>2%</td>
</tr>
<tr>
<td>AST</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade 2 (&gt;2.5-5.0 x ULN)</td>
<td>5%</td>
<td>3%</td>
</tr>
<tr>
<td>Grade 3 to 4 (&gt;5.0 x ULN)</td>
<td>3%</td>
<td>2%</td>
</tr>
<tr>
<td>Total Bilirubin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade 2 (1.6-2.5 x ULN)</td>
<td>3%</td>
<td>2%</td>
</tr>
<tr>
<td>Grade 3 to 4 (&gt;2.5 x ULN)</td>
<td>&lt;1%</td>
<td>&lt;1%</td>
</tr>
<tr>
<td>Creatine kinase</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade 2 (6.0-9.9 x ULN)</td>
<td>2%</td>
<td>5%</td>
</tr>
<tr>
<td>Grade 3 to 4 (≥10.0 x ULN)</td>
<td>7%</td>
<td>4%</td>
</tr>
<tr>
<td>Hyperglycemia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade 2 (126-250 mg/dL)</td>
<td>6%</td>
<td>6%</td>
</tr>
<tr>
<td>Grade 3 (&gt;250 mg/dL)</td>
<td>&lt;1%</td>
<td>2%</td>
</tr>
<tr>
<td>Lipase</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade 2 (&gt;1.5-3.0 x ULN)</td>
<td>7%</td>
<td>7%</td>
</tr>
<tr>
<td>Grade 3 to 4 (&gt;3.0 x ULN)</td>
<td>2%</td>
<td>5%</td>
</tr>
<tr>
<td>Total neutrophils</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade 2 (0.75-0.99 x 10⁹)</td>
<td>4%</td>
<td>3%</td>
</tr>
<tr>
<td>Grade 3 to 4 (&lt;0.75 x 10⁹)</td>
<td>2%</td>
<td>2%</td>
</tr>
</tbody>
</table>

ULN = Upper limit of normal.
Table 5. Mean Change from Baseline in Fasted Lipid Values in Treatment-Naïve Subjects in SPRING-2 (Week 96 Analysis) and SINGLE Trials (Week 144 Analysis)

<table>
<thead>
<tr>
<th>Laboratory Parameter Preferred Term</th>
<th>SPRING-2</th>
<th>SINGLE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>TIVICAY 50 mg Once Daily + 2 NRTIs (n = 403)</td>
<td>Raltegravir 400 mg Twice Daily + 2 NRTIs (n = 405)</td>
</tr>
<tr>
<td>Cholesterol (mg/dL)</td>
<td>8.1</td>
<td>10.1</td>
</tr>
<tr>
<td>HDL cholesterol (mg/dL)</td>
<td>2.0</td>
<td>2.3</td>
</tr>
<tr>
<td>LDL cholesterol (mg/dL)</td>
<td>5.1</td>
<td>6.1</td>
</tr>
<tr>
<td>Triglycerides (mg/dL)</td>
<td>6.7</td>
<td>6.6</td>
</tr>
</tbody>
</table>

*Subjects on lipid-lowering agents at baseline were excluded from these analyses (19 subjects in each arm in SPRING-2, and in SINGLE: TIVICAY + EPZICOM n = 30 and ATRIPLA n = 27). Ninety-four subjects initiated a lipid-lowering agent post-baseline; their last fasted on-treatment values (prior to starting the agent) were used regardless if they discontinued the agent (SPRING-2: TIVICAY n = 9, raltegravir n = 13; SINGLE: TIVICAY + EPZICOM n = 36 and ATRIPLA: n = 36).*
at the start of therapy with TIVICAY, particularly in the setting where anti-hepatitis therapy was withdrawn [see Warnings and Precautions (5.2)].

*Changes in Serum Creatinine:* Dolutegravir has been shown to increase serum creatinine due to inhibition of tubular secretion of creatinine without affecting renal glomerular function [see Clinical Pharmacology (12.2)]. Increases in serum creatinine occurred within the first 4 weeks of treatment and remained stable through 96 weeks. In treatment-naïve subjects, a mean change from baseline of 0.15 mg per dL (range: -0.32 mg per dL to 0.65 mg per dL) was observed after 96 weeks of treatment. Creatinine increases were comparable by background NRTIs and were similar in treatment-experienced subjects.

**Clinical Trials Experience in Pediatric Subjects**

IMPAACT P1093 is an ongoing multicenter, open-label, non-comparative trial of approximately 160 HIV-1-infected pediatric subjects aged 4 weeks to less than 18 years, of which 46 treatment-experienced, INSTI-naïve subjects aged 6 to less than 18 years have been enrolled [see Use in Specific Populations (8.4), Clinical Studies (14.2)].

The adverse reaction profile was similar to that for adults. Grade 2 ADRs reported by more than one subject were decreased neutrophil count (n = 3) and diarrhea (n = 2). There were no Grade 3 or 4 drug-related ADRs reported. No ADRs led to discontinuation.

The Grade 3 or 4 laboratory abnormalities reported in more than one subject were elevated total bilirubin (n = 3) and decreased neutrophil count (n = 2). The changes in mean serum creatinine were similar to those observed in adults.

**6.2 Postmarketing Experience**

In addition to adverse reactions reported from clinical trials, the following adverse reactions have been identified during postmarketing use. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

**Musculoskeletal**

Arthralgia, myalgia.

**7 DRUG INTERACTIONS**

**7.1 Effect of Dolutegravir on the Pharmacokinetics of Other Agents**

In vitro, dolutegravir inhibited the renal organic cation transporters, OCT2 (IC₅₀ = 1.93 microM) and multidrug and toxin extrusion transporter (MATE) 1 (IC₅₀ = 6.34 microM). In vivo, dolutegravir inhibits tubular secretion of creatinine by inhibiting OCT2 and potentially MATE1. Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide and metformin, Table 6) [see Contraindications (4), Drug Interactions (7.3)].
In vitro, dolutegravir inhibited the basolateral renal transporters, organic anion transporter (OAT) 1 (IC\textsubscript{50} = 2.12 microM) and OAT3 (IC\textsubscript{50} = 1.97 microM). However, in vivo, dolutegravir did not alter the plasma concentrations of tenofovir or para-amino hippurate, substrates of OAT1 and OAT3.

In vitro, dolutegravir did not inhibit (IC\textsubscript{50} greater than 50 microM) the following: cytochrome P450 (CYP)1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A, uridine diphosphate (UDP)-glucuronosyl transferase 1A1 (UGT1A1), UGT2B7, P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), bile salt export pump (BSEP), organic anion transporter polypeptide (OATP)1B1, OATP1B3, OCT1, multidrug resistance protein (MRP)2, or MRP4. In vitro, dolutegravir did not induce CYP1A2, CYP2B6, or CYP3A4. Based on these data and the results of drug interaction trials, dolutegravir is not expected to affect the pharmacokinetics of drugs that are substrates of these enzymes or transporters.

In drug interaction trials, dolutegravir did not have a clinically relevant effect on the pharmacokinetics of the following drugs: daclatasvir, tenofovir, methadone, midazolam, rilpivirine, and oral contraceptives containing norgestimate and ethinyl estradiol. Using cross-study comparisons to historical pharmacokinetic data for each interacting drug, dolutegravir did not appear to affect the pharmacokinetics of the following drugs: atazanavir, darunavir, efavirenz, etravirine, fosamprenavir, lopinavir, ritonavir, and boceprevir.

### 7.2 Effect of Other Agents on the Pharmacokinetics of Dolutegravir

Dolutegravir is metabolized by UGT1A1 with some contribution from CYP3A. Dolutegravir is also a substrate of UGT1A3, UGT1A9, BCRP, and P-gp in vitro. Drugs that induce those enzymes and transporters may decrease dolutegravir plasma concentration and reduce the therapeutic effect of dolutegravir.

Coadministration of dolutegravir and other drugs that inhibit these enzymes may increase dolutegravir plasma concentration.

Etravirine significantly reduced plasma concentrations of dolutegravir, but the effect of etravirine was mitigated by coadministration of lopinavir/ritonavir or darunavir/ritonavir, and is expected to be mitigated by atazanavir/ritonavir (Table 6) [see Drug Interactions (7.3), Clinical Pharmacology (12.3)].

In vitro, dolutegravir was not a substrate of OATP1B1, or OATP1B3.

Darunavir/ritonavir, lopinavir/ritonavir, rilpivirine, tenofovir, boceprevir, daclatasvir, prednisone, rifabutin, and omeprazole had no clinically significant effect on the pharmacokinetics of dolutegravir.

### 7.3 Established and Other Potentially Significant Drug Interactions

Table 6 provides clinical recommendations as a result of drug interactions with TIVICAY. These recommendations are based on either drug interaction trials or predicted interactions due to the
expected magnitude of interaction and potential for serious adverse events or loss of efficacy.
[See Dosage and Administration (2), Clinical Pharmacology (12.3).]

Table 6. Established and Other Potentially Significant Drug Interactions: Alterations in
Dose or Regimen May Be Recommended Based on Drug Interaction Trials or Predicted
Interactions [see Dosage and Administration (2)]

<table>
<thead>
<tr>
<th>Concomitant Drug Class: Drug Name</th>
<th>Effect on Concentration of Dolutegravir and/or Concomitant Drug</th>
<th>Clinical Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HIV-1 Antiviral Agents</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-nucleoside reverse transcriptase inhibitor: Etravirine&lt;sup&gt;a&lt;/sup&gt;</td>
<td>↓Dolutegravir</td>
<td>Use of TIVICAY with etravirine without coadministration of atazanavir/ritonavir, darunavir/ritonavir, or lopinavir/ritonavir is not recommended.</td>
</tr>
<tr>
<td>Non-nucleoside reverse transcriptase inhibitor: Efavirenz&lt;sup&gt;a&lt;/sup&gt;</td>
<td>↓Dolutegravir</td>
<td>Adjust dose of TIVICAY to 50 mg twice daily for treatment-naïve and treatment-experienced, INSTI-naïve adult patients. In pediatric patients, increase the weight-based dose to twice daily (Table 2). Use alternative combinations that do not include metabolic inducers where possible for INSTI-experienced patients with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance.&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Non-nucleoside reverse transcriptase inhibitor: Nevirapine</td>
<td>↓Dolutegravir</td>
<td>Avoid coadministration with nevirapine because there are insufficient data to make dosing recommendations.</td>
</tr>
<tr>
<td>Protease inhibitor: Fosamprenavir/ritonavir&lt;sup&gt;a&lt;/sup&gt;</td>
<td>↓Dolutegravir</td>
<td>Adjust dose of TIVICAY to 50 mg twice daily for treatment-naïve and treatment-experienced, INSTI-naïve adult patients. In pediatric patients, increase the weight-based dose to twice daily (Table 2). Use alternative combinations that do not include metabolic inducers where possible for INSTI-experienced patients</td>
</tr>
<tr>
<td>Tipranavir/ritonavir&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other Agents</td>
<td>Effect on Dolutegravir</td>
<td>Notes</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------</td>
<td>-------</td>
</tr>
<tr>
<td><strong>Carbamazepine&lt;sup&gt;a&lt;/sup&gt;</strong></td>
<td>↓Dolutegravir</td>
<td>Adjust dose of TIVICAY to 50 mg twice daily in treatment-naïve or treatment-experienced, INSTI-naïve adult patients. In pediatric patients, increase the weight-based dose to twice daily (Table 2). Use alternative treatment that does not include carbamazepine where possible for INSTI-experienced patients with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance.&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Oxcarbazepine</strong></td>
<td>↓Dolutegravir</td>
<td>Avoid coadministration with TIVICAY because there are insufficient data to make dosing recommendations.</td>
</tr>
<tr>
<td><strong>Phenytoin</strong></td>
<td>↓Dolutegravir</td>
<td></td>
</tr>
<tr>
<td><strong>Phenobarbital</strong></td>
<td>↓Dolutegravir</td>
<td></td>
</tr>
<tr>
<td><strong>St. John’s wort</strong> (&lt;i&gt;Hypericum perforatum&lt;/i&gt;)</td>
<td>↓Dolutegravir</td>
<td></td>
</tr>
<tr>
<td><strong>Medications containing polyvalent cations (e.g., Mg or Al):</strong> Cation-containing antacids&lt;sup&gt;a&lt;/sup&gt; or laxatives Sucralfate Buffered medications</td>
<td>↓Dolutegravir</td>
<td>Administer TIVICAY 2 hours before or 6 hours after taking medications containing polyvalent cations.</td>
</tr>
<tr>
<td><strong>Oral calcium or iron supplements, including multivitamins containing calcium or iron&lt;sup&gt;a&lt;/sup&gt;</strong></td>
<td>↓Dolutegravir</td>
<td>Administer TIVICAY 2 hours before or 6 hours after taking supplements containing calcium or iron. Alternatively, TIVICAY and supplements containing calcium or iron can be taken together with food.</td>
</tr>
<tr>
<td><strong>Metformin</strong></td>
<td>↑Metformin</td>
<td>With concomitant use, limit the total daily dose of metformin to 1,000 mg either when starting metformin or TIVICAY. When stopping TIVICAY, the metformin dose may require an</td>
</tr>
</tbody>
</table>

<sup>a</sup>Other Agents

- Carbamazepine
- Oxcarbazepine
- Phenytoin
- Phenobarbital
- St. John’s wort (<i>Hypericum perforatum</i>)
- Medications containing polyvalent cations (e.g., Mg or Al): Cation-containing antacids or laxatives Sucralfate Buffered medications
- Oral calcium or iron supplements, including multivitamins containing calcium or iron
- Metformin

<sup>b</sup>Other Agents

- Other Agents
- Other Agents
adjustment. Monitoring of blood glucose when initiating concomitant use and after withdrawal of TIVICAY is recommended.

| Rifampina | ↓Dolutegravir | Adjust dose of TIVICAY to 50 mg twice daily for treatment-naïve and treatment-experienced, INSTI-naïve adult patients. In pediatric patients, increase the weight-based dose to twice daily (Table 2). Use alternatives to rifampin where possible for INSTI-experienced patients with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance.\(^{b}\) |

\(^{a}\)See Clinical Pharmacology (12.3) Table 9 or Table 10 for magnitude of interaction.
\(^{b}\)The lower dolutegravir exposures observed in INSTI-experienced patients (with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance [see Microbiology (12.4)]) upon coadministration with certain inducers may result in loss of therapeutic effect and development of resistance to TIVICAY or other coadministered antiretroviral agents.

### 8 USE IN SPECIFIC POPULATIONS

#### 8.1 Pregnancy

**Pregnancy Exposure Registry**

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to TIVICAY during pregnancy. Healthcare providers are encouraged to register patients by calling the Antiretroviral Pregnancy Registry (APR) at 1-800-258-4263.

**Risk Summary**

There are insufficient human data on the use of TIVICAY during pregnancy to inform a drug-associated risk of birth defects and miscarriage. Given the limited number of pregnancies exposed to dolutegravir-based regimens reported to the APR, no definitive conclusions can be drawn on the safety of TIVICAY in pregnancy, and continued monitoring is ongoing through the APR. The background rate for major birth defects in a U.S. reference population of the Metropolitan Atlanta Congenital Defects Program (MACDP) is 2.7%. The estimated background rate of miscarriage in clinically recognized pregnancies in the U.S. general population is 15% to 20%. In animal reproduction studies, no evidence of adverse developmental outcomes was observed with dolutegravir [see Data]. During organogenesis in the rat and rabbit, systemic exposures (AUC) to dolutegravir were less than (rabbits) and approximately 27 times (rats) the
exposure in humans at the maximum recommended human dose (MRHD). In the rat pre/post-natal developmental study, maternal systemic exposure (AUC) to dolutegravir was approximately 27 times the exposure in humans at the MRHD.

Data

Animal Data: Dolutegravir was administered orally at up to 1,000 mg per kg daily to pregnant rats and rabbits on gestation Days 6 to 17 and 6 to 18, respectively, and also to rats on gestation day 6 to lactation/post-partum Day 20. No adverse effects on embryo-fetal (rats and rabbits) or pre/post-natal (rats) development were observed at up to the highest dose tested. During organogenesis systemic exposures (AUC) to dolutegravir in rabbits were less than the exposure in humans at the maximum recommended human dose (MRHD) and in rats were approximately 27 times the exposure in humans at the MRHD. In the rat pre/post-natal development study, decreased body weight of the developing offspring was observed during lactation at a maternally toxic dose (approximately 27 times human exposure at the MRHD).

8.2 Lactation

Risk Summary

The Centers for Disease Control and Prevention recommend that HIV-1-infected mothers in the United States not breastfeed their infants to avoid risking postnatal transmission of HIV-1 infection. It is not known whether TIVICAY is present in human breast milk, affects human milk production, or has effects on the breastfed infant. When administered to lactating rats, dolutegravir was present in milk [see Data].

Because of the potential for (1) HIV-1 transmission (in HIV-negative infants), and (2) developing viral resistance (in HIV-positive infants), instruct mothers not to breastfeed if they are receiving TIVICAY.

Data

Animal Data: Dolutegravir was the primary drug-related component excreted into the milk of lactating rats following a single oral dose of 50 mg per kg on lactation Day 10, with milk concentrations of up to approximately 1.3 times that of maternal plasma concentrations observed 8 hours post-dose.

8.4 Pediatric Use

The safety, virologic, and immunologic responses in subjects who received TIVICAY were evaluated in 46 treatment-experienced, INSTI-naïve, HIV-1–infected subjects aged 6 to less than 18 years in an open-label, multicenter, dose-finding clinical trial, IMPAACT P1093 [see Clinical Pharmacology (12.3), Clinical Studies (14.2)]. Frequency, type, and severity of adverse drug reactions among the 46 pediatric subjects were comparable to those observed in adults [see Adverse Reactions (6.2)]. In 17 subjects weighing at least 30 kg, pharmacokinetic parameters of dolutegravir were comparable to adults receiving 50 mg once daily [see Clinical Pharmacology (12.3)].
Safety and efficacy of TIVICAY have not been established in pediatric patients weighing less than 30 kg or in any pediatric patients who are INSTI-experienced.

8.5  Geriatric Use

Clinical trials of TIVICAY did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently from younger subjects. In general, caution should be exercised in the administration of TIVICAY in elderly patients reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy [see Clinical Pharmacology (12.3)].

8.6  Hepatic Impairment

No clinically important pharmacokinetic differences between subjects with moderate hepatic impairment and matching healthy subjects were observed. No dosage adjustment is necessary for patients with mild to moderate hepatic impairment (Child-Pugh Score A or B). The effect of severe hepatic impairment (Child-Pugh Score C) on the pharmacokinetics of dolutegravir has not been studied. Therefore, TIVICAY is not recommended for use in patients with severe hepatic impairment [see Clinical Pharmacology (12.3)].

8.7  Renal Impairment

Dolutegravir plasma concentrations were decreased in subjects with severe renal impairment compared with those in matched healthy controls. However, no dosage adjustment is necessary for treatment-naïve or treatment-experienced and INSTI-naïve patients with mild, moderate, or severe renal impairment or for INSTI-experienced patients (with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance) with mild or moderate renal impairment. Caution is warranted for INSTI-experienced patients (with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance [see Microbiology (12.4)]) with severe renal impairment, as the decrease in dolutegravir concentrations may result in loss of therapeutic effect and development of resistance to TIVICAY or other coadministered antiretroviral agents [see Clinical Pharmacology (12.3)]. Dolutegravir has not been studied in patients on dialysis.

10  OVERDOSAGE

There is no known specific treatment for overdose with TIVICAY. If overdose occurs, the patient should be monitored and standard supportive treatment applied as required. As dolutegravir is highly bound to plasma proteins, it is unlikely that it will be significantly removed by dialysis.

11  DESCRIPTION

TIVICAY contains dolutegravir, as dolutegravir sodium, an HIV INSTI. The chemical name of dolutegravir sodium is sodium (4R,12aS)-9-{{(2,4-difluorophenyl)methyl}carbamoyl}-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazin-7-olate. The
The empirical formula is $C_{20}H_{18}F_2N_3NaO_5$ and the molecular weight is 441.36 g per mol. It has the following structural formula:

![Structural formula of Dolutegravir sodium](image)

Dolutegravir sodium is a white to light yellow powder and is slightly soluble in water.

Each film-coated tablet of TIVICAY for oral administration contains 10.5, 26.3, or 52.6 mg of dolutegravir sodium, which is equivalent to 10, 25, or 50 mg dolutegravir free acid, respectively, and the following inactive ingredients: D-mannitol, microcrystalline cellulose, povidone K29/32, sodium starch glycolate, and sodium stearyl fumarate. The tablet film-coating contains the inactive ingredients iron oxide yellow (25-mg and 50-mg tablets only), macrogol/PEG, polyvinyl alcohol-part hydrolyzed, talc, and titanium dioxide.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Dolutegravir is an HIV-1 antiviral agent [see Microbiology (12.4)].

12.2 Pharmacodynamics

In a randomized, dose-ranging trial, HIV-1-infected subjects treated with dolutegravir monotherapy demonstrated rapid and dose-dependent antiviral activity with mean declines from baseline to Day 11 in HIV-1 RNA of 1.5, 2.0, and 2.5 $\log_{10}$ for dolutegravir 2 mg, 10 mg, and 50 mg once daily, respectively. This antiviral response was maintained for 3 to 4 days after the last dose in the 50-mg group.

Effects on Electrocardiogram

In a randomized, placebo-controlled, cross-over trial, 42 healthy subjects received single-dose oral administrations of placebo, dolutegravir 250-mg suspension (exposures approximately 3-fold of the 50-mg once-daily dose at steady state), and moxifloxacin 400 mg (active control) in random sequence. After baseline and placebo adjustment, the maximum mean QTc change based on Fridericia correction method (QTcF) for dolutegravir was 2.4 msec (1-sided 95% upper CI: 4.9 msec). TIVICAY did not prolong the QTc interval over 24 hours postdose.

Effects on Renal Function

The effect of dolutegravir on renal function was evaluated in an open-label, randomized, 3-arm, parallel, placebo-controlled trial in healthy subjects (n = 37) who received dolutegravir 50 mg once daily (n = 12), dolutegravir 50 mg twice daily (n = 13), or placebo once daily (n = 12) for
14 days. A decrease in creatinine clearance, as determined by 24-hour urine collection, was observed with both doses of dolutegravir after 14 days of treatment in subjects who received 50 mg once daily (9% decrease) and 50 mg twice daily (13% decrease). Neither dose of dolutegravir had a significant effect on the actual glomerular filtration rate (determined by the clearance of probe drug, iohexol) or effective renal plasma flow (determined by the clearance of probe drug, para-amino hippurate) compared with the placebo.

12.3 Pharmacokinetics

The pharmacokinetic properties of dolutegravir have been evaluated in healthy adult subjects and HIV-1-infected adult subjects. Exposure to dolutegravir was generally similar between healthy subjects and HIV-1-infected subjects. The non-linear exposure of dolutegravir following 50 mg twice daily compared with 50 mg once daily in HIV-1-infected subjects (Table 7) was attributed to the use of metabolic inducers in the background antiretroviral regimens of subjects receiving dolutegravir 50 mg twice daily in clinical trials. TIVICAY was administered without regard to food in these trials.

Table 7. Dolutegravir Steady-State Pharmacokinetic Parameter Estimates in HIV–1–Infected Adults

<table>
<thead>
<tr>
<th>Parameter</th>
<th>50 mg Once Daily Geometric Mean (CV)</th>
<th>50 mg Twice Daily Geometric Mean (CV)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUC(0-24) (mcg.h/mL)</td>
<td>53.6 (27)</td>
<td>75.1 (35)</td>
</tr>
<tr>
<td>Cmax (mcg/mL)</td>
<td>3.67 (20)</td>
<td>4.15 (29)</td>
</tr>
<tr>
<td>Cmin (mcg/mL)</td>
<td>1.11 (46)</td>
<td>2.12 (47)</td>
</tr>
</tbody>
</table>

a Based on population pharmacokinetic analyses using data from SPRING-1 and SPRING-2.
b Based on population pharmacokinetic analyses using data from VIKING (ING112961) and VIKING-3.

Absorption

Following oral administration of dolutegravir, peak plasma concentrations were observed 2 to 3 hours postdose. With once-daily dosing, pharmacokinetic steady state is achieved within approximately 5 days with average accumulation ratios for AUC, Cmax, and C24 h ranging from 1.2 to 1.5.

Dolutegravir plasma concentrations increased in a less than dose-proportional manner above 50 mg. Dolutegravir is a P-gp substrate in vitro. The absolute bioavailability of dolutegravir has not been established.

Effects of Food on Oral Absorption

TIVICAY may be taken with or without food. Food increased the extent of absorption and slowed the rate of absorption of dolutegravir. Low-, moderate-, and high-fat meals increased
dolutegravir AUC\(_{(0-\infty)}\) by 33%, 41%, and 66%; increased \(C_{\text{max}}\) by 46%, 52%, and 67%; and prolonged \(T_{\text{max}}\) to 3, 4, and 5 hours from 2 hours under fasted conditions, respectively.

**Distribution**

Dolutegravir is highly bound (greater than or equal to 98.9%) to human plasma proteins based on in vivo data and binding is independent of plasma concentration of dolutegravir. The apparent volume of distribution (Vd/F) following 50-mg once-daily administration is estimated at 17.4 L based on a population pharmacokinetic analysis.

*Cerebrospinal Fluid (CSF)*: In 12 treatment-naïve subjects on dolutegravir 50 mg daily plus abacavir/lamivudine, the median dolutegravir concentration in CSF was 13.2 ng per mL (range: 3.74 ng per mL to 18.3 ng per mL) 2 to 6 hours postdose after 16 weeks of treatment. The clinical relevance of this finding has not been established.

**Metabolism and Elimination**

Dolutegravir is primarily metabolized via UGT1A1 with some contribution from CYP3A. After a single oral dose of \([^{14}\text{C}]\) dolutegravir, 53% of the total oral dose was excreted unchanged in feces. Thirty-one percent of the total oral dose was excreted in urine, represented by an ether glucuronide of dolutegravir (18.9% of total dose), a metabolite formed by oxidation at the benzylic carbon (3.0% of total dose), and its hydrolytic N-dealkylation product (3.6% of total dose). Renal elimination of unchanged drug was low (less than 1% of the dose).

Dolutegravir has a terminal half-life of approximately 14 hours and an apparent clearance (CL/F) of 1.0 L per hour based on population pharmacokinetic analyses.

*Polymorphisms in Drug-Metabolizing Enzymes*: In a meta-analysis of healthy subject trials, subjects with UGT1A1 (\(n = 7\)) genotypes conferring poor dolutegravir metabolism had a 32% lower clearance of dolutegravir and 46% higher AUC compared with subjects with genotypes associated with normal metabolism via UGT1A1 (\(n = 41\)).

**Specific Populations**

*Hepatic Impairment*: Dolutegravir is primarily metabolized and eliminated by the liver. In a trial comparing 8 subjects with moderate hepatic impairment (Child-Pugh Score B) with 8 matched healthy controls, exposure of dolutegravir from a single 50-mg dose was similar between the 2 groups. No dosage adjustment is necessary for patients with mild to moderate hepatic impairment (Child-Pugh Score A or B). The effect of severe hepatic impairment (Child-Pugh Score C) on the pharmacokinetics of dolutegravir has not been studied. Therefore, Tivicay is not recommended for use in patients with severe hepatic impairment.

*HBV/HCV Co-infection*: Population analyses using pooled pharmacokinetic data from adult trials indicated no clinically relevant effect of HCV co-infection on the pharmacokinetics of dolutegravir. There were limited data on HBV co-infection.
Renal Impairment: Renal clearance of unchanged drug is a minor pathway of elimination for dolutegravir. In a trial comparing 8 subjects with severe renal impairment (CrCl less than 30 mL per min) with 8 matched healthy controls, AUC, C\text{max}, and C\text{24} of dolutegravir were decreased by 40%, 23%, and 43%, respectively, compared with those in matched healthy subjects. The cause of this decrease is unknown. Population pharmacokinetic analysis using data from SAILING and VIKING-3 trials indicated that mild and moderate renal impairment had no clinically relevant effect on the exposure of dolutegravir. No dosage adjustment is necessary for treatment-naïve or treatment-experienced and INSTI-naïve patients with mild, moderate, or severe renal impairment or for INSTI-experienced patients (with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance) with mild or moderate renal impairment. Caution is warranted for INSTI-experienced patients (with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance [see Microbiology (12.4)]) with severe renal impairment, as the decrease in dolutegravir concentrations may result in loss of therapeutic effect and development of resistance to TIVICAY or other coadministered antiretroviral agents. Dolutegravir has not been studied in patients requiring dialysis.

Gender: Population analyses using pooled pharmacokinetic data from adult trials indicated gender had no clinically relevant effect on the exposure of dolutegravir.

Race: Population analyses using pooled pharmacokinetic data from adult trials indicated race had no clinically relevant effect on the pharmacokinetics of dolutegravir.

Geriatric Patients: Population analyses using pooled pharmacokinetic data from adult trials indicated age had no clinically relevant effect on the pharmacokinetics of dolutegravir.

Pediatric Patients: The pharmacokinetics of dolutegravir in HIV-1-infected children (n = 17) weighing at least 30 kg were similar to those observed in HIV-1-infected adults who received dolutegravir 50 mg once daily (Table 8) [see Clinical Studies (14.2)].

Table 8. Dolutegravir Steady-State Pharmacokinetic Parameters in Pediatric Subjects

<table>
<thead>
<tr>
<th>Weight (n)</th>
<th>Dose of TIVICAY</th>
<th>Dolutegravir Pharmacokinetic Parameter Estimates Geometric Mean (%CV)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>C\text{max} (mcg/mL)</td>
</tr>
<tr>
<td>≥40 kg (n = 14)</td>
<td>50 mg once daily</td>
<td>3.89 (43)</td>
</tr>
<tr>
<td>≥30 to &lt;40 kg (n = 3)</td>
<td>35 mg once daily</td>
<td>4.40 (54)</td>
</tr>
</tbody>
</table>

Population pharmacokinetic analyses demonstrate comparable exposures in children, at least 30 kg, dosed by weight-bands (35 mg or 50 mg of dolutegravir) to that observed in adults.
Drug Interactions

Drug interaction trials were performed with TIVICAY and other drugs likely to be coadministered or commonly used as probes for pharmacokinetic interactions. As dolutegravir is not expected to affect the pharmacokinetics of other drugs dependent on hepatic metabolism (Table 9) [see Drug Interactions (7.1)], the primary focus of these drug interaction trials was to evaluate the effect of coadministered drug on dolutegravir (Table 10).

Dosing or regimen recommendations as a result of established and other potentially significant drug-drug interactions with TIVICAY are provided in Table 6 [see Dosage and Administration (2.1), Drug Interactions (7.3)].

Table 9. Summary of Effect of Dolutegravir on the Pharmacokinetics of Coadministered Drugs

<table>
<thead>
<tr>
<th>Coadministered Drug(s) and Dose(s)</th>
<th>Dose of TIVICAY</th>
<th>n</th>
<th>Geometric Mean Ratio (90% CI) of Pharmacokinetic Parameters of Coadministered Drug with/without Dolutegravir</th>
<th>No Effect = 1.00</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>C&lt;sub&gt;max&lt;/sub&gt;</td>
<td>AUC</td>
</tr>
<tr>
<td>Daclatasvir 60 mg once daily</td>
<td>50 mg once daily</td>
<td>12</td>
<td>1.03 (0.84 to 1.25)</td>
<td>0.98 (0.83 to 1.15)</td>
</tr>
<tr>
<td>Ethinyl estradiol 0.035 mg</td>
<td>50 mg twice daily</td>
<td>15</td>
<td>0.99 (0.91 to 1.08)</td>
<td>1.03 (0.96 to 1.11)</td>
</tr>
<tr>
<td>Metformin 500 mg twice daily</td>
<td>50 mg once daily</td>
<td>15&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1.66 (1.53 to 1.81)</td>
<td>1.79 (1.65 to 1.93)</td>
</tr>
<tr>
<td>Metformin 500 mg twice daily</td>
<td>50 mg twice daily</td>
<td>15&lt;sup&gt;a&lt;/sup&gt;</td>
<td>2.11 (1.91 to 2.33)</td>
<td>2.45 (2.25 to 2.66)</td>
</tr>
<tr>
<td>Methadone 16 to 150 mg</td>
<td>50 mg twice daily</td>
<td>11</td>
<td>1.00 (0.94 to 1.06)</td>
<td>0.98 (0.91 to 1.06)</td>
</tr>
<tr>
<td>Midazolam 3 mg</td>
<td>25 mg once daily</td>
<td>10</td>
<td>0.95 (0.79 to 1.15)</td>
<td>–</td>
</tr>
<tr>
<td>Norrelgestromin 0.25 mg</td>
<td>50 mg twice daily</td>
<td>15</td>
<td>0.89 (0.82 to 0.97)</td>
<td>0.98 (0.91 to 1.04)</td>
</tr>
<tr>
<td>Rilpivirine 25 mg once daily</td>
<td>50 mg once daily</td>
<td>16</td>
<td>1.10 (0.99 to 1.22)</td>
<td>1.06 (0.98 to 1.16)</td>
</tr>
<tr>
<td>Tenofovir disoproxil fumarate 300 mg once daily</td>
<td>50 mg once daily</td>
<td>15</td>
<td>1.09 (0.97 to 1.23)</td>
<td>1.12 (1.01 to 1.24)</td>
</tr>
</tbody>
</table>

<sup>a</sup>The number of subjects represents the maximum number of subjects that were evaluated.
Table 10. Summary of Effect of Coadministered Drugs on the Pharmacokinetics of Dolutegravir

<table>
<thead>
<tr>
<th>Coadministered Drug(s) and Dose(s)</th>
<th>Dose of TIVICAY</th>
<th>n</th>
<th>Geometric Mean Ratio (90% CI) of Dolutegravir Pharmacokinetic Parameters with/without Coadministered Drugs</th>
<th>No Effect = 1.00</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atazanavir 400 mg once daily</td>
<td>30 mg once daily</td>
<td>12</td>
<td>C&lt;sub&gt;max&lt;/sub&gt; 1.50 (1.40 to 1.59) AUC 1.91 (1.80 to 2.03) C&lt;sub&gt;T&lt;/sub&gt; or C&lt;sub&gt;24&lt;/sub&gt; 2.80 (2.52 to 3.11)</td>
<td></td>
</tr>
<tr>
<td>Atazanavir/ritonavir 300/100 mg once daily</td>
<td>30 mg once daily</td>
<td>12</td>
<td>1.34 (1.25 to 1.42) 1.62 (1.50 to 1.74) 2.21 (1.97 to 2.47)</td>
<td></td>
</tr>
<tr>
<td>Darunavir/ritonavir 600/100 mg twice daily</td>
<td>30 mg once daily</td>
<td>15</td>
<td>0.89 (0.83 to 0.97) 0.78 (0.72 to 0.85) 0.62 (0.56 to 0.69)</td>
<td></td>
</tr>
<tr>
<td>Efavirenz 600 mg once daily</td>
<td>50 mg once daily</td>
<td>12</td>
<td>0.61 (0.51 to 0.73) 0.43 (0.35 to 0.54) 0.25 (0.18 to 0.34)</td>
<td></td>
</tr>
<tr>
<td>Etravirine 200 mg twice daily</td>
<td>50 mg once daily</td>
<td>16</td>
<td>0.48 (0.43 to 0.54) 0.29 (0.26 to 0.34) 0.12 (0.09 to 0.16)</td>
<td></td>
</tr>
<tr>
<td>Etravirine + darunavir/ritonavir 200 mg + 600/100 mg twice daily</td>
<td>50 mg once daily</td>
<td>9</td>
<td>0.88 (0.78 to 1.00) 0.75 (0.69 to 0.81) 0.63 (0.52 to 0.76)</td>
<td></td>
</tr>
<tr>
<td>Etravirine + lopinavir/ritonavir 200 mg + 400/100 mg twice daily</td>
<td>50 mg once daily</td>
<td>8</td>
<td>1.07 (1.02 to 1.13) 1.11 (1.02 to 1.20) 1.28 (1.13 to 1.45)</td>
<td></td>
</tr>
<tr>
<td>Fosamprenavir/ritonavir 700 mg/100 mg twice daily</td>
<td>50 mg once daily</td>
<td>12</td>
<td>0.76 (0.63 to 0.92) 0.65 (0.54 to 0.78) 0.51 (0.41 to 0.63)</td>
<td></td>
</tr>
<tr>
<td>Lopinavir/ritonavir 400/100 mg twice daily</td>
<td>30 mg once daily</td>
<td>15</td>
<td>1.00 (0.94 to 1.07) 0.97 (0.91 to 1.04) 0.94 (0.85 to 1.05)</td>
<td></td>
</tr>
<tr>
<td>Rilpivirine 25 mg once daily</td>
<td>50 mg once daily</td>
<td>16</td>
<td>1.13 (1.06 to 1.21) 1.12 (1.05 to 1.19) 1.22 (1.15 to 1.30)</td>
<td></td>
</tr>
<tr>
<td>Tenofovir 300 mg once daily</td>
<td>50 mg once daily</td>
<td>15</td>
<td>0.97 (0.87 to 1.08) 1.01 (0.91 to 1.11) 0.92 (0.82 to 1.04)</td>
<td></td>
</tr>
<tr>
<td>Tipranavir/ritonavir 500/200 mg twice daily</td>
<td>50 mg once daily</td>
<td>14</td>
<td>0.54 (0.50 to 0.57) 0.41 (0.38 to 0.44) 0.24 (0.21 to 0.27)</td>
<td></td>
</tr>
<tr>
<td>Antacid (Maalox&lt;sup&gt;®&lt;/sup&gt;) simultaneous administration</td>
<td>50 mg single dose</td>
<td>16</td>
<td>0.28 (0.23 to 0.33) 0.26 (0.22 to 0.32) 0.26 (0.21 to 0.31)</td>
<td></td>
</tr>
<tr>
<td>Antacid (Maalox&lt;sup&gt;®&lt;/sup&gt;) 2 h after dolutegravir</td>
<td>50 mg single dose</td>
<td>16</td>
<td>0.82 (0.69 to 0.98) 0.74 (0.62 to 0.90) 0.70 (0.58 to 0.85)</td>
<td></td>
</tr>
<tr>
<td>Boceprevir 800 mg every 8 hours</td>
<td>50 mg once daily</td>
<td>13</td>
<td>1.05 (0.96 to 1.15) 1.07 (0.95 to 1.20) 1.08 (0.91 to 1.28)</td>
<td></td>
</tr>
<tr>
<td>Calcium carbonate 1,200 mg simultaneous administration (fasted)</td>
<td>50 mg single dose</td>
<td>12</td>
<td>0.63 (0.50 to 0.81) 0.61 (0.47 to 0.80) 0.61 (0.47 to 0.80)</td>
<td></td>
</tr>
<tr>
<td>Drug</td>
<td>Dose</td>
<td>N</td>
<td>IC50 Value</td>
<td>Lower 95% CI</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>-----------------------</td>
<td>----</td>
<td>------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Calcium carbonate 1,200 mg</td>
<td>50 mg single dose</td>
<td>11</td>
<td>1.07</td>
<td>(0.83 to 1.38)</td>
</tr>
<tr>
<td>simultaneous administration (fed)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calcium carbonate 1,200 mg</td>
<td>50 mg single dose</td>
<td>11</td>
<td>1.00</td>
<td>(0.78 to 1.29)</td>
</tr>
<tr>
<td>2 h after dolutegravir</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carbamazepine 300 mg twice daily</td>
<td>50 mg once daily</td>
<td>16</td>
<td>0.67</td>
<td>(0.61 to 0.73)</td>
</tr>
<tr>
<td>Daclatasvir 60 mg once daily</td>
<td>50 mg once daily</td>
<td>12</td>
<td>1.29</td>
<td>(1.07 to 1.57)</td>
</tr>
<tr>
<td>Ferrous fumarate 324 mg</td>
<td>50 mg single dose</td>
<td>11</td>
<td>0.43</td>
<td>(0.35 to 0.52)</td>
</tr>
<tr>
<td>simultaneous administration (fasted)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ferrous fumarate 324 mg</td>
<td>50 mg single dose</td>
<td>11</td>
<td>1.03</td>
<td>(0.84 to 1.26)</td>
</tr>
<tr>
<td>simultaneous administration (fed)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ferrous fumarate 324 mg</td>
<td>50 mg single dose</td>
<td>10</td>
<td>0.99</td>
<td>(0.81 to 1.21)</td>
</tr>
<tr>
<td>2 h after dolutegravir</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multivitamin (One-A-Day®)</td>
<td>50 mg single dose</td>
<td>16</td>
<td>0.65</td>
<td>(0.54 to 0.77)</td>
</tr>
<tr>
<td>simultaneous administration</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Omeprazole 40 mg once daily</td>
<td>50 mg single dose</td>
<td>12</td>
<td>0.92</td>
<td>(0.75 to 1.11)</td>
</tr>
<tr>
<td>Prednisone 60 mg once daily with taper</td>
<td>50 mg once daily</td>
<td>12</td>
<td>1.06</td>
<td>(0.99 to 1.14)</td>
</tr>
<tr>
<td>Rifampin 600 mg once daily</td>
<td>50 mg twice daily</td>
<td>11</td>
<td>0.57</td>
<td>(0.49 to 0.65)</td>
</tr>
<tr>
<td>Rifampin 600 mg once daily</td>
<td>50 mg twice daily</td>
<td>11</td>
<td>1.18</td>
<td>(1.03 to 1.37)</td>
</tr>
<tr>
<td>Rifabutin 300 mg once daily</td>
<td>50 mg once daily</td>
<td>9</td>
<td>1.16</td>
<td>(0.98 to 1.37)</td>
</tr>
</tbody>
</table>

**a** Comparison is rifampin taken with dolutegravir 50 mg twice daily compared with dolutegravir 50 mg twice daily.

**b** Comparison is rifampin taken with dolutegravir 50 mg twice daily compared with dolutegravir 50 mg once daily.

**c** The number of subjects represents the maximum number of subjects that were evaluated.

### 12.4 Microbiology

#### Mechanism of Action

Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral deoxyribonucleic acid (DNA) integration which is essential for the HIV replication cycle. Strand transfer biochemical assays using purified HIV-1 integrase and pre-processed substrate DNA resulted in IC50 values of 2.7 nM and 12.6 nM.

#### Antiviral Activity in Cell Culture
Dolutegravir exhibited antiviral activity against laboratory strains of wild-type HIV-1 with mean EC$_{50}$ values of 0.5 nM (0.21 ng per mL) to 2.1 nM (0.85 ng per mL) in peripheral blood mononuclear cells (PBMCs) and MT-4 cells. Dolutegravir exhibited antiviral activity against 13 clinically diverse clade B isolates with a mean EC$_{50}$ value of 0.52 nM in a viral integrase susceptibility assay using the integrase coding region from clinical isolates. Dolutegravir demonstrated antiviral activity in cell culture against a panel of HIV-1 clinical isolates (3 in each group of Mc lades A, B, C, D, E, F, and G, and 3 in group O) with EC$_{50}$ values ranging from 0.02 nM to 2.14 nM for HIV-1. Dolutegravir EC$_{50}$ values against 3 HIV-2 clinical isolates in PBMC assays ranged from 0.09 nM to 0.61 nM.

**Antiviral Activity in Combination with Other Antiviral Agents**

The antiviral activity of dolutegravir was not antagonistic when combined with the INSTI, raltegravir; non-nucleoside reverse transcriptase inhibitors (NNRTIs), efavirenz or nevirapine; the nucleoside reverse transcriptase inhibitors (NRTIs), abacavir or stavudine; the protease inhibitors (PIs), amprenavir or lopinavir; the CCR5 co-receptor antagonist, maraviroc; or the fusion inhibitor, enfuvirtide. Dolutegravir antiviral activity was not antagonistic when combined with the HBV reverse transcriptase inhibitor, adefovir, or inhibited by the antiviral, ribavirin.

**Resistance**

**Cell Culture:** Dolutegravir-resistant viruses were selected in cell culture starting from different wild-type HIV-1 strains and clades. Amino acid substitutions E92Q, G118R, S153F or Y, G193E or R263K emerged in different passages and conferred decreased susceptibility to dolutegravir of up to 4-fold. Passage of mutant viruses containing the Q148R or Q148H substitutions selected for additional substitutions in integrase that conferred decreased susceptibility to dolutegravir (fold-change increase of 13 to 46). The additional integrase substitutions included T97A, E138K, G140S, and M154I. Passage of mutant viruses containing both G140S and Q148H selected for L74M, E92Q, and N155H.

**Treatment-Naïve Subjects:** No subjects in the dolutegravir 50-mg once-daily treatment arms of treatment-naïve trials SPRING-2 (96 weeks) and SINGLE (144 weeks) had a detectable decrease in susceptibility to dolutegravir or background NRTIs in the resistance analysis subset (n = 12 with HIV-1 RNA greater than 400 copies per mL at failure or last visit and having resistance data). Two virologic failure subjects in SINGLE had treatment-emergent G/D/E193D and G193G/E integrase substitutions at Week 84 and Week 108, respectively, and 1 subject with 275 copies per mL HIV-1 RNA had a treatment-emergent Q157Q/P integrase substitution detected at Week 24. None of these subjects had a corresponding decrease in dolutegravir susceptibility. No treatment-emergent genotypic resistance to the background regimen was observed in the dolutegravir arm in either the SPRING-2 or SINGLE trials. No treatment-emergent primary resistance substitutions were observed in either treatment group in the FLAMINGO trial through Week 96.
Treatment-Experienced, Integrase Strand Transfer Inhibitor-Naïve Subjects: In the dolutegravir arm of the SAILING trial for treatment-experienced and INSTI-naïve subjects (n = 354), treatment-emergent integrase substitutions were observed in 6 of 28 (21%) subjects who had virologic failure and resistance data. In 5 of the 6 subjects’ isolates emergent INSTI substitutions included L74L/M/I, Q95Q/L, V151V/I (n = 1 each), and R263K (n = 2). The change in dolutegravir phenotypic susceptibility for these 5 subject isolates was less than 2-fold. One subject isolate had pre-existing raltegravir resistance substitutions E138A, G140S, and Q148H at baseline and had additional emergent INSTI-resistance substitutions T97A and E138A/T with a corresponding 148-fold reduction in dolutegravir susceptibility at failure. In the comparator raltegravir arm, 21 of 49 (43%) subjects with post-baseline resistance data had evidence of emergent INSTI-resistance substitutions (L74M, E92Q, T97A, E138Q, G140S/A, Y143R/C, Q148H/R, V151I, N155H, E157Q, and G163K/R) and raltegravir phenotypic resistance.

Treatment-Experienced, Integrase Strand Transfer Inhibitor-Experienced Subjects: VIKING-3 examined the efficacy of dolutegravir 50 mg twice daily plus optimized background therapy in subjects with prior or current virologic failure on an INSTI- (elvitegravir or raltegravir) containing regimen.

In VIKING-4 (ING116529), 30 subjects with current virological failure on an INSTI-containing regimen and genotypic evidence of INSTI-resistance substitutions at screening were randomized to receive either dolutegravir 50 mg twice daily or placebo with the current failing regimen for 7 days and then all subjects received open-label dolutegravir plus optimized background regimen from Day 8. Virologic responses at Week 48 by baseline genotypic and phenotypic INSTI-resistance categories and the INSTI resistance-associated substitutions that emerged on dolutegravir treatment in VIKING-4 were consistent with those seen in VIKING-3.

Response by Baseline Genotype

Of the 183 subjects with baseline data, 30% harbored virus with a substitution at Q148, and 33% had no primary INSTI-resistance substitutions (T66A/I/K, E92Q/V, Y143R/C/H, Q148H/R/K, and N155H) at baseline, but had historical genotypic evidence of INSTI-resistance substitutions, phenotypic evidence of elvitegravir or raltegravir resistance, or genotypic evidence of INSTI-resistance substitutions at screening.

Response rates by baseline genotype were analyzed in an “as-treated” analysis at Week 48 (n = 175) (Table 11). The response rate at Week 48 to dolutegravir-containing regimens was 47% (24 of 51) when Q148 substitutions were present at baseline; Q148 was always present with additional INSTI-resistance substitutions (see Table 11). In addition, a diminished virologic response of 40% (6 of 15) was observed when the substitution E157Q or K was present at baseline with other INSTI-resistance substitutions but without a Q148H or R substitution.
Table 11. Response by Baseline Integrase Genotype in Subjects with Prior Experience to an Integrase Strand Transfer Inhibitor in VIKING-3

<table>
<thead>
<tr>
<th>Baseline Genotype</th>
<th>Week 48 (&lt;50 copies/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall Response</td>
<td>66% (116/175)</td>
</tr>
<tr>
<td>No Q148 substitution(^a)</td>
<td>74% (92/124)</td>
</tr>
<tr>
<td>Q148H/R + G140S/A/C without additional INSTI-resistance substitution(^b)</td>
<td>61% (17/28)</td>
</tr>
<tr>
<td>Q148H/R + ≥2 INSTI-resistance substitutions(^b,c)</td>
<td>29% (6/21)</td>
</tr>
</tbody>
</table>

\(^a\) Includes INSTI-resistance substitutions Y143R/C/H and N155H.
\(^c\) The most common pathway with Q148H/R + greater than or equal to 2 INSTI-resistance substitutions had Q148+G140+E138 substitutions (n = 16).

Response by Baseline Phenotype

Response rates by baseline phenotype were analyzed in an as-treated analysis using all subjects with available baseline phenotypes through Week 48 (n = 163) (see Table 12). These baseline phenotypic groups are based on subjects enrolled in VIKING-3 and are not meant to represent definitive clinical susceptibility cut points for dolutegravir. The data are provided to guide clinicians on the likelihood of virologic success based on pretreatment susceptibility to dolutegravir in INSTI-resistant patients.

Table 12. Response by Baseline Dolutegravir Phenotype (Fold-Change from Reference) in Subjects with Prior Experience to an Integrase Strand Transfer Inhibitor in VIKING-3

<table>
<thead>
<tr>
<th>Baseline Dolutegravir Phenotype (Fold-Change from Reference)</th>
<th>Response at Week 48 (&lt;50 copies/mL) Subset n = 163</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall Response</td>
<td>64% (104/163)</td>
</tr>
<tr>
<td>&lt;3-fold change</td>
<td>72% (83/116)</td>
</tr>
<tr>
<td>3-&lt;10-fold change</td>
<td>53% (18/34)</td>
</tr>
<tr>
<td>≥10-fold change</td>
<td>23% (3/13)</td>
</tr>
</tbody>
</table>

Integrase Strand Transfer Inhibitor Treatment-Emergent Resistance

There were 50 subjects with virologic failure on the dolutegravir twice-daily regimen in VIKING-3 with HIV-1 RNA greater than 400 copies per mL at the failure timepoint, Week 48 or beyond, or the last timepoint on trial. Thirty-nine subjects with virologic failure had resistance data that were used in the Week 48 analysis. In the Week 48 resistance analysis 85% (33 of 39)
of the subjects with virologic failure had treatment-emergent INSTI-resistance substitutions in their isolates. The most common treatment-emergent INSTI-resistance substitution was T97A. Other frequently emergent INSTI-resistance substitutions included L74M, I or V, E138K or A, G140S, Q148H, R or K, M154I, or N155H. Substitutions E92Q, Y143R or C/H, S147G, V151A, and E157E/Q each emerged in 1 to 3 subjects’ isolates. At failure, the median dolutegravir fold-change from reference was 61-fold (range: 0.75 to 209) for isolates with emergent INSTI-resistance substitutions (n = 33).

Resistance to one or more background drugs in the dolutegravir twice-daily regimen also emerged in 49% (19 of 39) subjects in the Week 48 resistance analysis.

**Cross-Resistance**

*Site-Directed Integrase Strand Transfer Inhibitor-Resistant Mutant HIV-1 and HIV-2 Strains:* The susceptibility of dolutegravir was tested against 60 INSTI-resistant site-directed mutant HIV-1 viruses (28 with single substitutions and 32 with 2 or more substitutions) and 6 INSTI-resistant site-directed mutant HIV-2 viruses. The single INSTI-resistance substitutions T66K, I151L, and S153Y conferred a greater than 2-fold decrease in dolutegravir susceptibility (range: 2.3-fold to 3.6-fold from reference). Combinations of multiple substitutions T66K/L74M, E92Q/N155H, G140C/Q148R, G140S/Q148H, R or K, Q148R/N155H, T97A/G140S/Q148, and substitutions at E138/G140/Q148 showed a greater than 2-fold decrease in dolutegravir susceptibility (range: 2.5-fold to 21-fold from reference). In HIV-2 mutants, combinations of substitutions A153G/N155H/S163G and E92Q/T97A/N155H/S163D conferred 4-fold decreases in dolutegravir susceptibility, and E92Q/N155H and G140S/Q148R showed 8.5-fold and 17-fold decreases in dolutegravir susceptibility, respectively.

*Reverse Transcriptase Inhibitor- and Protease Inhibitor-Resistant Strains:* Dolutegravir demonstrated equivalent antiviral activity against 2 NNRTI-resistant, 3 NRTI-resistant, and 2 PI-resistant HIV-1 mutant clones compared with the wild-type strain.

### 13 NONCLINICAL TOXICOLOGY

#### 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

**Carcinogenesis**

Two-year carcinogenicity studies in mice and rats were conducted with dolutegravir. Mice were administered doses of up to 500 mg per kg, and rats were administered doses of up to 50 mg per kg. In mice, no significant increases in the incidence of drug-related neoplasms were observed at the highest doses tested, resulting in dolutegravir AUC exposures approximately 14-fold higher than those in humans at the recommended dose of 50 mg twice daily. In rats, no increases in the incidence of drug-related neoplasms were observed at the highest dose tested, resulting in dolutegravir AUC exposures 10-fold and 15-fold higher in males and females, respectively, than those in humans at the recommended dose of 50 mg twice daily.
Mutagenesis

Dolutegravir was not genotoxic in the bacterial reverse mutation assay, mouse lymphoma assay, or in the in vivo rodent micronucleus assay.

Impairment of Fertility

In a study conducted in rats, there were no effects on mating or fertility with dolutegravir up to 1,000 mg per kg per day. This dose is associated with an exposure that is approximately 24 times higher than the exposure in humans at the recommended dose of 50 mg twice daily.

14 CLINICAL STUDIES

The efficacy of TIVICAY is based on analyses of data from 3 trials, SPRING-2 (ING113086), SINGLE (ING114467), and FLAMINGO (ING114915), in treatment-naïve, HIV-1-infected subjects (n = 2,125); one trial, SAILING (ING111762), in treatment-experienced, INSTI-naïve HIV-1-infected subjects (n = 715); and from VIKING-3 (ING12574) trial in INSTI-experienced HIV-1-infected subjects (n = 183). The use of TIVICAY in pediatric patients aged 6 years and older is based on evaluation of safety, pharmacokinetics, and efficacy in a multicenter, open-label trial in subjects without INSTI resistance.

14.1 Adult Subjects

Treatment-Naïve Subjects

In SPRING-2, 822 subjects were randomized and received at least 1 dose of either TIVICAY 50 mg once daily or raltegravir 400 mg twice daily, both in combination with fixed-dose dual NRTI treatment (either abacavir sulfate and lamivudine [EPZICOM] or emtricitabine/tenofovir [TRUVADA]). There were 808 subjects included in the efficacy and safety analyses. At baseline, the median age of subjects was 36 years, 13% female, 15% non-white, 11% had hepatitis B and/or C virus co-infection, 2% were CDC Class C (AIDS), 28% had HIV-1 RNA greater than 100,000 copies per mL, 48% had CD4+ cell count less than 350 cells per mm³, and 39% received EPZICOM; these characteristics were similar between treatment groups.

In SINGLE, 833 subjects were randomized and received at least 1 dose of either TIVICAY 50 mg once daily with fixed-dose abacavir sulfate and lamivudine (EPZICOM) or fixed-dose efavirenz/emtricitabine/tenofovir (ATRIPLA). At baseline, the median age of subjects was 35 years, 16% female, 32% non-white, 7% had hepatitis C co-infection (hepatitis B virus co-infection was excluded), 4% were CDC Class C (AIDS), 32% had HIV-1 RNA greater than 100,000 copies per mL, and 53% had CD4+ cell count less than 350 cells per mm³; these characteristics were similar between treatment groups.

Outcomes for SPRING-2 (Week 96 analysis) and SINGLE (Week 144 open-label phase analysis which followed the Week 96 double-blind phase) are provided in Table 13. Side-by-side tabulation is to simplify presentation; direct comparisons across trials should not be made due to differing trial designs.
Table 13. Virologic Outcomes of Randomized Treatment in SPRING-2 at Week 96 and SINGLE at Week 144 (Snapshot Algorithm)

<table>
<thead>
<tr>
<th></th>
<th>SPRING-2 Week 96</th>
<th>Raltegravir 400 mg Twice Daily + 2 NRTIs (n = 405)</th>
<th>SINGLE Week 144</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV-1 RNA &lt;50 copies/mL</td>
<td>82%</td>
<td>78%</td>
<td>71%</td>
</tr>
<tr>
<td>Treatment difference(^a)</td>
<td>4.9% (95% CI: -0.6%, 10.3%)(^d)</td>
<td>8.3% (95% CI: 2.0%, 14.6%)(^c)</td>
<td></td>
</tr>
<tr>
<td>Virologic nonresponse</td>
<td>5%</td>
<td>10%</td>
<td>10%</td>
</tr>
<tr>
<td>Data in window not &lt;50 copies/mL</td>
<td>1%</td>
<td>3%</td>
<td>4%</td>
</tr>
<tr>
<td>Discontinued for lack of efficacy</td>
<td>2%</td>
<td>3%</td>
<td>3%</td>
</tr>
<tr>
<td>Discontinued for other reasons while not suppressed</td>
<td>&lt;1%</td>
<td>3%</td>
<td>3%</td>
</tr>
<tr>
<td>Change in ART regimen</td>
<td>&lt;1%</td>
<td>&lt;1%</td>
<td>0%</td>
</tr>
<tr>
<td>No virologic data Reasons</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discontinued study/study drug due to adverse event or death(^b)</td>
<td>2%</td>
<td>2%</td>
<td>4%</td>
</tr>
<tr>
<td>Discontinued study/study drug for other reasons(^c)</td>
<td>8%</td>
<td>9%</td>
<td>12%</td>
</tr>
<tr>
<td>Missing data during window but on study</td>
<td>2%</td>
<td>&lt;1%</td>
<td>2%</td>
</tr>
<tr>
<td>Proportion (%) of Subjects with HIV-1 RNA &lt;50 copies/mL by Baseline Category</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma viral load (copies/mL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤100,000</td>
<td>84%</td>
<td>83%</td>
<td>73%</td>
</tr>
<tr>
<td>&gt;100,000</td>
<td>79%</td>
<td>63%</td>
<td>69%</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>84%</td>
<td>79%</td>
<td>72%</td>
</tr>
<tr>
<td>Female</td>
<td>70%</td>
<td>68%</td>
<td>69%</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>83%</td>
<td>78%</td>
<td>72%</td>
</tr>
<tr>
<td>African-American/African Heritage/Other</td>
<td>77%</td>
<td>75%</td>
<td>71%</td>
</tr>
</tbody>
</table>

\(^a\) Adjusted for pre-specified stratification factors.
Includes subjects who discontinued due to an adverse event or death at any time point if this resulted in no virologic data on treatment during the analysis window.

Other includes reasons such as withdrew consent, loss to follow-up, moved, and protocol deviation.

The primary endpoint was assessed at Week 48 and the virologic success rate was 88% in the group receiving TIVICAY and 86% in the raltegravir group, with a treatment difference of 2.6% and 95% CI of (-1.9%, 7.2%).

The primary endpoint was assessed at Week 48 and the virologic success rate was 88% in the group receiving TIVICAY and 81% in the ATRIPLA group, with a treatment difference of 7.4% and 95% CI of (2.5%, 12.3%).

**SPRING-2:** Virologic outcomes were also comparable across baseline characteristics including CD4+ cell count, age, and use of EPZICOM or TRUVADA as NRTI background regimen. The median change in CD4+ cell counts from baseline were 276 cells per mm$^3$ in the group receiving TIVICAY and 264 cells per mm$^3$ for the raltegravir group at 96 weeks.

There was no treatment-emergent resistance to dolutegravir or to the NRTI background.

**SINGLE:** Treatment differences were maintained across baseline characteristics including baseline viral load, CD4+ cell count, age, gender, and race.

The adjusted mean changes in CD4+ cell counts from baseline were 378 cells per mm$^3$ in the group receiving TIVICAY + EPZICOM and 332 cells per mm$^3$ for the ATRIPLA group at 144 weeks. The adjusted difference between treatment arms and 95% CI was 46.9 cells per mm$^3$ (15.6 cells per mm$^3$, 78.2 cells per mm$^3$) (adjusted for pre-specified stratification factors: baseline HIV-1 RNA, and baseline CD4+ cell count).

There was no treatment-emergent resistance to dolutegravir, abacavir, or lamivudine.

**FLAMINGO:** In FLAMINGO, 485 subjects were randomized and received at least 1 dose of either TIVICAY 50 mg once daily (n = 243) or darunavir + ritonavir 800 mg/100 mg once daily (n = 242), both in combination with investigator-selected NRTI background regimen (either fixed-dose abacavir and lamivudine [EPZICOM] or fixed-dose emtricitabine/tenofovir disoproxil fumarate [TRUVADA]). There were 484 subjects included in the efficacy and safety analyses. At baseline, the median age of subjects was 34 years, 15% female, 28% non-white, 10% had hepatitis B and/or C virus co-infection, 3% were CDC Class C (AIDS), 25% had HIV-1 RNA greater than 100,000 copies per mL, and 35% had CD4+ cell count less than 350 cells per mm$^3$; these characteristics were similar between treatment groups. Overall response rates by Snapshot algorithm through Week 96 were 80% for TIVICAY and 68% for darunavir/ritonavir. The proportion of subjects who were non-responders (HIV-1 RNA greater than or equal to 50 copies per mL) at Week 96 was 8% and 12% in the arms receiving TIVICAY and darunavir + ritonavir, respectively; no virologic data were available for 12% and 21% for subjects treated with TIVICAY and darunavir + ritonavir, respectively. The adjusted overall response rate difference
in proportion and 95% CI was 12.4% (4.7%, 20.2%). No treatment-emergent primary resistance substitutions were observed in either treatment group.

Treatment-Experienced, Integrase Strand Transfer Inhibitor-Naïve Subjects

In the international, multicenter, double-blind trial (SAILING), 719 HIV-1-infected, antiretroviral treatment-experienced adults were randomized and received either TIVICAY 50 mg once daily or ralt Gravigir 400 mg twice daily with investigator-selected background regimen consisting of up to 2 agents, including at least 1 fully active agent. There were 715 subjects included in the efficacy and safety analyses. At baseline, the median age was 43 years, 32% were female, 50% non-white, 16% had hepatitis B and/or C virus co-infection, 46% were CDC Class C (AIDS), 20% had HIV-1 RNA greater than 100,000 copies per mL, and 72% had CD4+ cell count less than 350 cells per mm³; these characteristics were similar between treatment groups. All subjects had at least 2-class antiretroviral treatment resistance, and 49% of subjects had at least 3-class antiretroviral treatment resistance at baseline. Week 48 outcomes for SAILING are shown in Table 14.

Table 14. Virologic Outcomes of Randomized Treatment in SAILING at 48 Weeks (Snapshot Algorithm)

<table>
<thead>
<tr>
<th></th>
<th>TIVICAY 50 mg Once Daily + BR(^a) (n = 354)</th>
<th>Raltegravir 400 mg Twice Daily + BR(^a) (n = 361)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV-1 RNA &lt;50 copies/mL</td>
<td>71%</td>
<td>64%</td>
</tr>
<tr>
<td>Adjusted(^b) treatment difference</td>
<td>7.4% (95% CI: 0.7%, 14.2%)</td>
<td></td>
</tr>
<tr>
<td>Virologic nonresponse</td>
<td>20%</td>
<td>28%</td>
</tr>
<tr>
<td>No virologic data Reasons</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discontinued study/study drug due to adverse event or death</td>
<td>3%</td>
<td>4%</td>
</tr>
<tr>
<td>Discontinued study/study drug for other reasons(^c)</td>
<td>5%</td>
<td>4%</td>
</tr>
<tr>
<td>Missing data during window but on study</td>
<td>2%</td>
<td>1%</td>
</tr>
</tbody>
</table>

Proportion (%) with HIV-1 RNA <50 copies/mL by Baseline Category

<table>
<thead>
<tr>
<th>Plasma viral load (copies/mL)</th>
<th>TIVICAY 50 mg Once Daily + BR(^a)</th>
<th>Raltegravir 400 mg Twice Daily + BR(^a)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤50,000 copies/mL</td>
<td>75%</td>
<td>71%</td>
</tr>
<tr>
<td>&gt;50,000 copies/mL</td>
<td>62%</td>
<td>47%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Background regimen</th>
<th>TIVICAY 50 mg Once Daily + BR(^a)</th>
<th>Raltegravir 400 mg Twice Daily + BR(^a)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No darunavir use</td>
<td>67%</td>
<td>60%</td>
</tr>
<tr>
<td>Darunavir use with primary PI substitutions</td>
<td>85%</td>
<td>67%</td>
</tr>
<tr>
<td>Darunavir use without primary PI substitutions</td>
<td>69%</td>
<td>70%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gender</th>
<th>TIVICAY 50 mg Once Daily + BR(^a)</th>
<th>Raltegravir 400 mg Twice Daily + BR(^a)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>70%</td>
<td>66%</td>
</tr>
<tr>
<td>Female</td>
<td>74%</td>
<td>60%</td>
</tr>
</tbody>
</table>
### Race

<table>
<thead>
<tr>
<th>Race</th>
<th>75%</th>
<th>67%</th>
</tr>
</thead>
<tbody>
<tr>
<td>White</td>
<td>71%</td>
<td>57%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Race</th>
<th>75%</th>
<th>67%</th>
</tr>
</thead>
<tbody>
<tr>
<td>African-American/African Heritage/Other</td>
<td>71%</td>
<td>57%</td>
</tr>
</tbody>
</table>

a BR = Background regimen. Background regimen was restricted to less than or equal to 2 antiretroviral treatments with at least 1 fully active agent.
b Adjusted for pre-specified stratification factors.
c Other includes reasons such as withdrew consent, loss to follow-up, moved, and protocol deviation.

Treatment differences were maintained across the baseline characteristics including CD4+ cell count and age.

The mean changes in CD4+ cell counts from baseline were 162 cells per mm$^3$ in the group receiving TIVICAY and 153 cells per mm$^3$ in the raltegravir group.

**Treatment-Experienced, Integrase Strand Transfer Inhibitor-Experienced Subjects**

VIKING-3 examined the effect of TIVICAY 50 mg twice daily over 7 days of functional monotherapy, followed by optimized background therapy (OBT) with continued treatment of TIVICAY 50 mg twice daily.

In the multicenter, open-label, single-arm VIKING-3 trial, 183 HIV-1-infected, antiretroviral treatment-experienced adults with virological failure and current or historical evidence of raltegravir and/or elvitegravir resistance received TIVICAY 50 mg twice daily with the current failing background regimen for 7 days, then received TIVICAY with OBT from Day 8. A total of 183 subjects enrolled: 133 subjects with INSTI resistance at screening and 50 subjects with only historical evidence of resistance (and not at screening). At baseline, median age of subjects was 48 years; 23% were female, 29% non-white, and 20% had hepatitis B and/or C virus co-infection. Median baseline CD4+ cell count was 140 cells per mm$^3$, median duration of prior antiretroviral treatment was 13 years, and 56% were CDC Class C. Subjects showed multiple-class antiretroviral treatment resistance at baseline: 79% had greater than or equal to 2 NRTI, 75% greater than or equal to 1 NNRTI, and 71% greater than or equal to 2 PI major substitutions; 62% had non-R5 virus.

Mean reduction from baseline in HIV-1 RNA at Day 8 (primary endpoint) was $1.4 \log_{10}$ (95% CI: $1.3 \log_{10}$, $1.5 \log_{10}$). Response at Week 48 was affected by baseline INSTI substitutions [see Microbiology (12.4)].

After the functional monotherapy phase, subjects had the opportunity to re-optimize their background regimen when possible. Week 48 virologic outcomes for VIKING-3 are shown in Table 15.
Table 15. Virologic Outcomes of Treatment of VIKING-3 at 48 Weeks (Snapshot Algorithm)

<table>
<thead>
<tr>
<th>HIV-1 RNA &lt;50 copies/mL</th>
<th>TIVICAY 50 mg Twice Daily + OBT (n = 183)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Virologic nonresponse</td>
<td>63%</td>
</tr>
</tbody>
</table>

No virologic data

<table>
<thead>
<tr>
<th>Reasons</th>
<th>3%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discontinued study/study drug due to adverse event or death</td>
<td></td>
</tr>
</tbody>
</table>

Proportion (%) with HIV-1 RNA <50 copies/mL by Baseline Category

<table>
<thead>
<tr>
<th>Gender</th>
<th>Male</th>
<th>63%</th>
<th>Female</th>
<th>64%</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Race</th>
<th>White</th>
<th>63%</th>
<th>African-American/African Heritage/Other</th>
<th>64%</th>
</tr>
</thead>
</table>

Subjects harboring virus with Q148 and with additional Q148-associated secondary substitutions also had a reduced response at Week 48 in a stepwise fashion [see Microbiology (12.4)].

The median change in CD4+ cell count from baseline was 80 cells per mm$^3$ at Week 48.

14.2 Pediatric Subjects

IMPAACT P1093 is a Phase 1/2, 48-week, multicenter, open-label trial to evaluate the pharmacokinetic parameters, safety, tolerability, and efficacy of TIVICAY in combination treatment regimens in HIV–1-infected infants, children, and adolescents. Subjects were stratified by age, enrolling adolescents first (Cohort 1: aged 12 to less than 18 years) and then younger children (Cohort 2A: aged 6 to less than 12 years). All subjects received a weight-based dose of TIVICAY [see Dosage and Administration (2.2)].

These 46 subjects had a mean age of 12 years (range: 6 to 17), were 54% female and 52% black. At baseline, mean plasma HIV-1 RNA was 4.6 log$_{10}$ copies per mL, median CD4+ cell count was 639 cells per mm$^3$ (range: 9 to 1,700), and median CD4+% was 23% (range: 1% to 44%). Overall, 39% had baseline plasma HIV-1 RNA greater than 50,000 copies per mL and 33% had a CDC HIV clinical classification of category C. Most subjects had previously used at least 1 NNRTI (50%) or 1 PI (70%).

At Week 24, the proportion of subjects with HIV-1 RNA less than 50 copies per mL in Cohort 1 and Cohort 2A was 70% (16/23) and 61% (14/23), respectively. At Week 48, the proportion of subjects from Cohort 1 with HIV-1 RNA less than 50 copies per mL was 61% (14/23). Virologic outcomes were also evaluated based on body weight. Across both cohorts, virologic suppression (HIV-1 RNA less than 50 copies per mL) at Week 24 was achieved in 75% (18/24) of subjects weighing at least 40 kg and 55% (6/11) of subjects in the 30 to less than 40 kg weight-band. At
Week 48, 63% (12/19) of the subjects in Cohort 1 weighing at least 40 kg were virologically suppressed.

The median CD4+ cell count increase from baseline to Week 48 was 84 cells per mm³ in Cohort 1. For Cohort 2A, the median CD4+ cell count increase from baseline to Week 24 was 209 cells per mm³.

16 HOW SUPPLIED/STORAGE AND HANDLING

TIVICAY tablets, 10 mg, are white, round, film-coated, biconvex tablets debossed with “SV 572” on one side and “10” on the other side. Bottle of 30 tablets with child-resistant closure and containing a desiccant. NDC 49702-226-13.

Store and dispense the 10-mg tablets in the original package, protect from moisture, and keep the bottle tightly closed. Do not remove desiccant.

TIVICAY tablets, 25 mg, are pale yellow, round, film-coated, biconvex tablets debossed with “SV 572” on one side and “25” on the other side. Bottle of 30 tablets with child-resistant closure. NDC 49702-227-13.

TIVICAY tablets, 50 mg, are yellow, round, film-coated, biconvex tablets debossed with “SV 572” on one side and “50” on the other side. Bottle of 30 tablets with child-resistant closure. NDC 49702-228-13.

Store at 25°C (77°F); excursions permitted 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature].

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Drug Interactions

TIVICAY is contraindicated with dofetilide because interactions between these drugs can result in potentially life-threatening adverse events [see Contraindications (4)].

Hypersensitivity Reactions

Advise patients to immediately contact their healthcare provider if they develop rash. Instruct patients to immediately stop taking TIVICAY and other suspect agents, and seek medical attention if they develop a rash associated with any of the following symptoms, as it may be a sign of a more serious reaction such as severe hypersensitivity: fever; generally ill feeling; extreme tiredness; muscle or joint aches; blisters or peeling of the skin; oral blisters or lesions; eye inflammation; facial swelling; swelling of the eyes, lips, tongue, or mouth; breathing difficulty; and/or signs and symptoms of liver problems (e.g., yellowing of the skin or whites of the eyes, dark or tea-colored urine, pale-colored stools or bowel movements, nausea, vomiting,
loss of appetite, or pain, aching, or sensitivity on the right side below the ribs) [see Warnings and Precautions (5.1)].

**Effects on Serum Liver Biochemistries in Patients with Hepatitis B or C Co-infection**

Advise patients that it is recommended to have laboratory testing before and during therapy as patients with underlying hepatitis B or C may be at increased risk for worsening or development of transaminase elevations with use of TIVICAY [see Warnings and Precautions (5.2)].

**Fat Redistribution**

Inform patients that redistribution or accumulation of body fat may occur in patients receiving antiretroviral therapy and that the cause and long-term health effects of these conditions are not known at this time [see Warnings and Precautions (5.3)].

**Immune Reconstitution Syndrome**

Advise patients to inform their healthcare provider immediately of any signs or symptoms of infection as inflammation from previous infection may occur soon after combination antiretroviral therapy, including when TIVICAY is started [see Warnings and Precautions (5.4)].

**Pregnancy Registry**

Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to TIVICAY during pregnancy [see Use in Specific Populations (8.1)].

**Lactation**

Instruct women with HIV-1 infection not to breastfeed because HIV-1 can be passed to the baby in the breast milk [see Use in Specific Populations (8.2)].

**Missed Dosage**

Instruct patients that if they miss a dose of TIVICAY, to take it as soon as they remember. Advise patients not to double their next dose or take more than the prescribed dose [see Dosage and Administration (2)].

**Storage**

Instruct patients to store the TIVICAY 10-mg tablets in the original package, keep the bottle tightly closed, and protect from moisture. Do not remove desiccant [see How Supplied/Storage and Handling (16)].

TIVICAY and EPZICOM are registered trademarks of the Viiv Healthcare group of companies. The other brands listed are trademarks of their respective owners and are not trademarks of the Viiv Healthcare group of companies. The makers of these brands are not affiliated with and do not endorse the Viiv Healthcare group of companies or its products.
### PATIENT INFORMATION

**TIVICAY® (TIV-eh-kay)**
(dolutegravir)
tablets

**What is the most important information I should know about TIVICAY?**

**Allergic reactions.** Call your healthcare provider right away if you develop a rash with TIVICAY. **Stop taking TIVICAY and get medical help right away if you:**

- develop a rash with any of the following signs or symptoms:
  - fever
  - generally ill feeling
  - extreme tiredness
  - muscle or joint aches
  - blisters or sores in mouth
  - blisters or peeling of the skin
  - redness or swelling of the eyes
  - swelling of the mouth, face, lips, or tongue
  - problems breathing

- develop any of the following signs or symptoms of liver problems:
  - your skin or the white part of your eyes turn yellow (jaundice)
  - dark or “tea-colored” urine
  - light-colored stools (bowel movements)
  - pain, aching, or tenderness on the right side of your stomach area
  - nausea
  - loss of appetite for several days or longer

**What is TIVICAY?**

TIVICAY is a prescription medicine that is used together with other antiretroviral medicines to treat Human Immunodeficiency Virus (HIV-1) infection in adults and children who weigh at least 66 pounds.

HIV-1 is the virus that causes Acquired Immune Deficiency Syndrome (AIDS).

It is not known if TIVICAY is safe and effective in children who weigh less than 66 pounds or in children who have received certain types of medicine for HIV-1 infection.

**Who should not take TIVICAY?**

Do not take TIVICAY if you:

- have ever had an allergic reaction to a medicine that contains dolutegravir (TIVICAY, TRIUMEQ®).
- take dofetilide (TIKOSYN®). Taking TIVICAY and dofetilide (TIKOSYN) can cause side effects that may be serious or life-threatening.

**What should I tell my healthcare provider before taking TIVICAY?**

Before you take TIVICAY, tell your healthcare provider if you:

- have ever had an allergic reaction to TIVICAY.
- have had liver problems, including hepatitis B or C infection.
- have any other medical condition.
- are pregnant or plan to become pregnant. It is not known if TIVICAY will harm your unborn baby. Tell your healthcare provider if you become pregnant while taking TIVICAY.
Pregnancy Registry. There is a pregnancy registry for women who take antiretroviral medicines during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry.

- are breastfeeding or plan to breastfeed. **Do not breastfeed if you take Tivicay.**
  - you should not breastfeed if you have HIV-1 because of the risk of passing HIV-1 to your baby.
  - Talk with your healthcare provider about the best way to feed your baby.

Tell your healthcare provider about the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements.

Some medicines interact with Tivicay. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine. You can ask your healthcare provider or pharmacist for a list of medicines that interact with Tivicay.

Over-the-counter medicines that interact with Tivicay include:

- St. John’s wort (*Hypericum perforatum*). Avoid use of St. John’s wort with Tivicay.
- antacids, laxatives, or other medicines that contain aluminum, magnesium, sucralfate (CARAFATE®), or buffered medicines. Tivicay should be taken at least 2 hours before or 6 hours after you take antacids, laxatives, or other medicines that contain aluminum, magnesium, sucralfate (CARAFATE), or buffered medicines.
- iron or calcium supplements taken by mouth. Supplements containing calcium or iron may be taken at the same time with Tivicay if taken with food. Otherwise, Tivicay should be taken at least 2 hours before or 6 hours after you take these medicines.

- **Do not start taking a new medicine without telling your healthcare provider.** Your healthcare provider can tell you if it is safe to take Tivicay with other medicines.

**How should I take Tivicay?**

- **Take Tivicay exactly as your healthcare provider tells you to take it.**
- If you miss a dose of Tivicay, take it as soon as you remember. Do not take 2 doses at the same time or take more than what your healthcare provider tells you to take.
- Stay under the care of a healthcare provider during treatment with Tivicay.
- Tivicay may be taken with or without food.
- Do not run out of Tivicay. The virus in your blood may increase and the virus may become harder to treat. When your supply starts to run low, get more from your healthcare provider or pharmacy.
- If you take too much Tivicay, call your healthcare provider or go to the nearest hospital emergency room right away.

**What are the possible side effects of Tivicay?**

- **Tivicay can cause serious side effects including:**
- See “What is the most important information I should know about Tivicay?”
- **Changes in liver tests.** People with a history of hepatitis B or C virus may have an increased risk of developing new or worsening changes in certain liver tests during treatment with Tivicay. Your healthcare provider may do tests to check your liver function before and during treatment with Tivicay.
• **Changes in body fat can happen in people who take HIV-1 medicines.** These changes may include increased amount of fat in the upper back and neck ("buffalo hump"), breast, and around the middle of your body (trunk). Loss of fat from the legs, arms, and face may also happen. The exact cause and long-term health effects of these problems are not known.

• **Changes in your immune system (Immune Reconstitution Syndrome) can happen when you start taking HIV-1 medicines.** Your immune system may get stronger and begin to fight infections that have been hidden in your body for a long time. Tell your healthcare provider right away if you start having new symptoms after you start taking Tivicay.

• **The most common side effects of Tivicay include:**
  - trouble sleeping
  - tiredness
  - headache

Tell your healthcare provider about any side effect that bothers you or that does not go away.

These are not all the possible side effects of Tivicay. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

**How should I store Tivicay?**

• Store Tivicay at room temperature between 68°F to 77°F (20°C to 25°C).

• The bottle of Tivicay (10-mg tablets) contains a desiccant packet to help keep your medicine dry (protect it from moisture). Keep the desiccant packet in the bottle. Do not remove the desiccant packet.

• Store Tivicay 10-mg tablets in the original bottle. Keep the bottle tightly closed and protected from moisture.

**Keep Tivicay and all medicines out of the reach of children.**

**General information about the safe and effective use of Tivicay.**

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use Tivicay for a condition for which it was not prescribed. Do not give Tivicay to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for information about Tivicay that is written for health professionals. For more information, go to www.Tivicay.com or call 1-877-844-8872.

**What are the ingredients in Tivicay?**

**Active ingredient:** dolutegravir sodium.

**Inactive ingredients:** d-mannitol, microcrystalline cellulose, povidone K29/32, sodium starch glycolate, and sodium stearyl fumarate. The tablet film-coating contains the inactive ingredients iron oxide yellow (for the 25-mg and 50-mg tablets), macrogol/PEG, polyvinyl alcohol-part hydrolyzed, talc, and titanium dioxide.

Manufactured for: Viiv Healthcare

Research Triangle Park, NC 27709

by:

GlaxoSmithKline

Research Triangle Park, NC 27709
TIVICAY and TRIUMEQ are registered trademarks of the Viiv Healthcare group of companies.

The other brands listed are trademarks of their respective owners and are not trademarks of the Viiv Healthcare group of companies. The makers of these brands are not affiliated with and do not endorse the Viiv Healthcare group of companies or its products.

©2016 the Viiv Healthcare group of companies. All rights reserved.

TVC:6PIL

This Patient Information has been approved by the U.S. Food and Drug Administration.
Revised: 06/2016